WO1993025243A2 - Metal complexes formed with macrocyclic ligands for use in imaging techniques - Google Patents

Metal complexes formed with macrocyclic ligands for use in imaging techniques Download PDF

Info

Publication number
WO1993025243A2
WO1993025243A2 PCT/US1993/005532 US9305532W WO9325243A2 WO 1993025243 A2 WO1993025243 A2 WO 1993025243A2 US 9305532 W US9305532 W US 9305532W WO 9325243 A2 WO9325243 A2 WO 9325243A2
Authority
WO
WIPO (PCT)
Prior art keywords
metal
complex
group
macrocyclic ligand
macrocyclic
Prior art date
Application number
PCT/US1993/005532
Other languages
French (fr)
Other versions
WO1993025243A3 (en
Inventor
Quintus Fernando
Michiko Inoue
Motomichi Inoue
Original Assignee
Research Corporation Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corporation Technologies, Inc. filed Critical Research Corporation Technologies, Inc.
Publication of WO1993025243A2 publication Critical patent/WO1993025243A2/en
Publication of WO1993025243A3 publication Critical patent/WO1993025243A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA

Definitions

  • the invention relates to novel macrocyclic ligands with pendant carboxylic acid groups and their corresponding metal complexes which are useful in imaging techniques such as Magnetic Resonance Imaging (MRI), X-ray Contrast Imaging, Positron Emission Tomography (PET), and Single Photo Emission Computer Tomography (SPECT). If the ligands are complexed with a radioisotope and bound to a monoclonal antibody, they can be used in immuno-imaging and immuno-therapy.
  • MRI Magnetic Resonance Imaging
  • PET Positron Emission Tomography
  • SPECT Single Photo Emission Computer Tomography
  • nonradioactive or radioactive metals such as gadolinium or yttrium 90 are used.
  • Contrast enhancers are often needed when dealing with living subjects so that one can distinguish tissues which are histologically dissimilar but magnetically similar.
  • Ligands which can complex with radioactive metals are also needed in the immuno-imaging and immuno-therapy fields. To be useful in these areas the macrocyclic ligand must be able to bind a radioisotope and also link to a monoclonal antibody.
  • the macrocyclic ligand is functionalized, for example with a pendant aminoalkyl group and then linked by a bifunctional linker molecule to amino acid residues on a monoclonal antibody.
  • These ligands can be directed with great selectivity to specific targeted sites in a living subject. This selectivity is achieved by using a monoclonal antibody that binds strongly to antigens that are associated with the targeted sites.
  • the present invention encompasses various macrocyclic ligands, their corresponding metal complexes, methods of using the complexes in imaging techniques and a process for synthesizing the ligands.
  • a macrocyclic ligand according to the following formula is provided:
  • A is selected from the group consisting of:
  • B is selected from the group consisting of:
  • n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
  • w is selected to be the same as either m or n;
  • R 1 , R 2 , R 3 is H or any alkyl group.
  • a macrocyclic ligand according to the following formula is provided:
  • A is selected from the group consisting of
  • B is selected from the group consisting of
  • n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
  • w is selected to be the same as m or n; and R 1 , R 2 , R 3 is H or any alkyl group.
  • a macrocyclic ligand according to the following formula is provided:
  • A is selected from the group consisting of:
  • B is selected from the group consisting of:
  • C is selected from the group consisting of:
  • n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, or 4;
  • w is selected to be the same as m or n;
  • R 1 , R 2 , R 3 is H or any alkyl group
  • a macrocyclic ligand having the formula is provided:
  • a metal selected from the group consisting of any metal ion in the +1, +2, +3 or +4 oxidation state is complexed with a macrocyclic ligand having the formula:
  • A is selected from the group consisting of:
  • n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
  • w is selected to be the same as m or n;
  • R 1 , R 2 , R 3 is H or any alkyl group.
  • a metal selected from the group consisting of any metal ion in the +1, +2, +3 or +4 oxidation state is complexed with a macrocyclic ligand having the formula:
  • A is selected from the group consisting of:
  • B is selected from the group consisting of:
  • n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
  • w is selected to be the same as m or n;
  • R 1 , R 2 , R 3 is H or any alkyl group.
  • a method for enhancing contrast in imaging techniques used on living subjects includes administering internally to the subject an effective amount of a contrast agent.
  • the contrast agent comprises a complex of a metal selected from the group consisting of any metal ion that is in the +1, +2, +3 or +4 oxidation state and a macrocyclic ligand having the formula:
  • A is selected from the group consisting of:
  • B is selected from the group consisting of:
  • n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
  • w is selected to be the same as m or n;
  • R 1 , R 2 , R 3 is H or any alkyl group.
  • a method for enhancing contrast in imaging techniques used on living subjects includes administering internally to the subject an effective amount of a contrast agent.
  • the contrast agent comprises a complex of a metal selected from the group consisting of any metal ion that is in the +1, +2, +3 or +4 oxidation state and a macrocyclic ligand having the formula:
  • A is selected from the group consisting of:
  • B is selected from the group consisting of:
  • w is selected to be the same as m or n;
  • R 1 , R 1 , R 2 is H or any alkyl group
  • FIGURE 1 shows the molecular structure of a
  • FIGURE 2 shows the crystal packing in a unit cell of the structure of FIGURE 1.
  • FIGURE 3 shows the molecular structure of a
  • FIGURE 4 shows the crystal packing in a unit cell of the structure of FIGURE 3.
  • FIGURE 5 shows the stereoscopic view of a preferred ligand-metal complex of the present invention.
  • FIGURE 6 shows the crystal packing in a unit cell of the structure of FIGURE 5.
  • FIGURE 7 shows the stereoscopic view of the
  • FIGURE 8 shows the molecular structure of a
  • FIGURE 9 shows the tetradecahedron around the metal of the complex of FIGURE 8.
  • FIGURE 10 shows the structure of a preferred ligand-metal complex of the present invention.
  • FIGURE 11 shows the tetradecahedron around the metal of the complex of FIGURE 10.
  • Macrocyclic ligands with pendant carboxylic acid groups can be prepared by condensation reactions between a polyalkylpolyaminopolycarboxylic dianhydride and a alkylpolyamine or a polyalkylpolyamine. The reaction occurs in a single step and the product is obtained in relatively high yield without the use of any template metal ions.
  • the metal complexes of these ligands will be formed readily, especially if the ligand has the same number of displaceable protons as the charge on the metal ion.
  • the metal complexes of these ligands have unusual structures because the metal ions are coordinated not only to the nitrogen donors, but also to the pendant carboxylic acid groups.
  • the complexes are useful in imaging techniques such as Magnetic Resonance Imaging (MRI), X-Ray Contrast Imaging, Positron Emission Tomography (PET), Single Photo Emission Computer Tomography (SPECT) and Dual X-Ray Absorptiometry (DEXA).
  • MRI Magnetic Resonance Imaging
  • PET Positron Emission Tomography
  • SPECT Single Photo Emission Computer Tomography
  • DEXA Dual X-Ray Absorptiometry
  • ligands of the present invention are complexed with a radioisotope and a targeting molecule such as a monoclonal antibody or a fragment of an
  • the complexes are useful in immuno-therapy and immuno-imaging.
  • Any metal ion having a +1, +2, +3 or +4 oxidation number can be used to form a complex with the ligands of the present invention.
  • the preferred metals are
  • A is selected from the group consisting of:
  • Bz is selected from the group consisting of:
  • m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
  • w can be either m or n
  • R 1 , R 2 , R 3 is H or any alkyl group.
  • A (CH 2 ) x
  • A is selected from the group consisting of
  • B is selected from the group consisting of
  • n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
  • w is selected to be the same as m or n;
  • R 1 , R 2 , R 3 is H or any alkyl group.
  • A is selected from the group consisting of:
  • B is selected from the group consisting of:
  • C is selected from the group consisting of:
  • m, n, t, u, v, w, x, y, z are independentlt selected from the integers 1, 2, 3, 4;
  • w is selected to be the same as m or n;
  • R 1 , R 2 , R 3 Is H or any alkyl group.
  • Figures 1-11 are various views of the presently preferred metal complexes of the presently preferred macrocyclic ligands of the instant invention.
  • FIG. 1 shows the molecular structure of
  • CuL(12).4H 2 O and Figure 2 shows the crystal packing in the unit cell of CuL (12).4H 2 O.
  • Table 1 summaries the crystal data.
  • Tables 2 and 3 show the selected bond distances and bond angles.
  • Table 4 shows the positional parameters of the non-hydrogen atoms.
  • L(12) consists of a 12-membered ring with amide bonds and contains two pendant carboxylic acid groups.
  • One of the amide groups is not coordinated to the metal ion.
  • the 12-membered ring is too small to involve the metal ion inside its macrocyclic cavity.
  • Water molecules are hydrogen-bonded to each other and are not coordinated to copper.
  • Figure 3 shows the structure and Figure 4 shows the crystal packing in the unit cell of Mn 2 L(24).8H2O.
  • Table 5 shows the positional parameters of the non- hydrogen atoms.
  • the bond distances and the bond angles are collected in Tables 6 and 7.
  • L(24) has a 24-membered ring and four pendant carboxylic acid groups. Each ligand is coordinated to two manganese ions. The
  • resulting manganese chelate molecule has C 2 symmetry, the symmetry axis of which coincides with the crystal C 2 axis and passes perpendicular to the averaged molecular plane of the macrocyclic ring.
  • the manganese atoms within a chelate molecule are, therefore, crystallographically equivalent to each other.
  • the Mn-O distances of 2.111-2.212 A are significantly shorter than the Mn-N distance of 2.358-2.445 A.
  • An additional weak bond is formed between a Mn atom and an amide oxygen atom 06 with a distance of 2.686 ⁇ .
  • a distorted seven-coordination geometry is established around the metal atoms.
  • the 24-membered macrocyclic ligand was obtained as an amorphous powder, whereas its Mn(II) complex was obtained in a crystalline form. Chelate formation with metal ions makes the ring rigid and results in a well- defined configuration of the chelate ring.
  • Extensive hydrogen bonding occurs in the crystal lattice structure and defines the arrangement of the metal chelate molecules in the crystal.
  • a water molecule occupies a special position on the crystal C 2 axis that coincides with the C 2 axis of the metal chelate ring.
  • This water molecule forms strong hydrogen bonds with two water molecules (OW1) coordinated to Mn and also with two amide oxygen atoms that are weakly bonded to Mn. These hydrogen bonds firmly link the two Mn ions within a chelate ring and define the molecular structure of the metal chelate.
  • Figure 5 shows a stereoscopic view of PbL(13).
  • the crystal packing diagram is shown in Figure 6.
  • Figure 7 shows a stereoscopic view of the coordination geometry around the Pb(II) ion.
  • Table 8 shows the bond distances and angles.
  • Table 9 shows the fractional coordinates and equivalent isotropic temperature factors.
  • L(13) forms a non-ionic neutral Pb(II) complex.
  • a ligand molecule is coordinated to a Pb(II) ion with two carboxylato oxygen atoms, O(3) and O(5), two amide oxygen atoms, O(1) and O(2), and two amine nitrogen atoms, N(1) and N(2).
  • All these donor atoms are located in half the coordination sphere because the ligand is unable to occupy all the positions in the coordination sphere of the metal ion.
  • the remaining coordination positions are occupied by a water oxygen atom (OW1) and a carboxylato oxygen atom O(4') from the adjacent metal chelate. If the very long Pb-O(4') distance of 3.223 ⁇ is considered to be a Pb-0 bond, the resulting molecule is a binuclear chelate.
  • the water molecule (OW1), that is coordinated to the Pb(II) ion forms a hydrogen bond with O(3') of the adjacent metal chelate, thereby stabilizing the binuclear chelate.
  • Other hydrogen bonds with the O-O distance less than 2.9 ⁇ are found for OW1-O(6), OW2-O(4) and OW3-O(6) atomic pairs.
  • the coordination geometry around the Pb(II) ion that includes the two distant atoms O(2) and O(4) can be described as a highly distorted dodecahedron.
  • polyhedron is much longer than the O(1)-N(l) distance (2.803 ⁇ ); these distances would be equal in a regular dodecahedron with D 2d symmetry.
  • the -C-CO-N-C- atoms in each amide group are on the same plane; the largest deviation from the averaged plane is 0.09 ⁇ for the amide N(4)HC (2) O(1), and 0.014 ⁇ for
  • Figure 8 shows the stereoview of GdL (15).8H20, the atoms are shown at a 20% probability level.
  • Figure 9 shows the tetradecahedron around the Gd ion in Gd
  • Table 11 shows the positional parameters of GdL (15).8H 2 O.
  • Table 12 shows the positional parameters of YL(15).8H 2 O.
  • Table 13 shows the M-X and C-O bond distances.
  • Table 14 shows the bond angles. The X-ray results show that the 15-membered macrocyclic ligand has three pendant
  • Each ligand molecule is coordinated to two Gd ions and each metal ion has nine coordination bonds with: two carboxylato oxygen atoms O(3) and O(5), an amide oxygen atom O(1) and two amine nitrogen atoms N(l) and N(2) from one ligand molecule; a carboxylato oxygen atom O(7), an amide oxygen atom O(2) and an amine nitrogen atom N(3) from the second ligand molecule and a water oxygen atom (OW1).
  • Two metal ions are located between two ligand molecules, forming a binuclear metal chelate, in which the averaged molecular planes of the two macrocyclic rings are parallel to each other.
  • the resulting metal chelate molecules have an inversion center with the result that the two metal ions are crystallographically equivalent to each other.
  • Figure 10 shows the structure of GdL (16).4H2O, the atoms are shown at a 50% probability level.
  • Figure 11 shows the tetradecahedron around the Gd ion.
  • Table 10 summarizes the crystal data.
  • Table 15 shows the
  • Each metal ion has nine coordination bonds with: two amide oxygen atoms O(1) and O(2), three carboxylato oxygen atoms O(3), O(5) and O(7) and three amine nitrogen atoms N(1), N(2) and N(3) from a single ligand molecule, and a water oxygen atom (OW1). Therefore, the ligand molecule occupies all the coordination sites around the Gd(II) ion jointly with a water molecule.
  • a water molecule is strongly coordinated to a metal ion, and the amide oxygen atoms are coordinated to metal ions, whereas none of the amide nitrogen atoms is bonded to a metal ion.
  • the L(15) ligand is coordinated to two Gd(III) ions resulting in a binuclear chelate, whereas the L(16) ligand is coordinated to single metal ion and forms a mononuclear molecule.
  • the coordination geometries in both Gd(III) chelates are described as tricapped trigonal prisms. However, the sequences of the coordinated atoms in the tetradecahedrons are quite different from each other. The tetradecahedron in the GdL(15) chelate is highly distorted from the ideal D 3h geometry.
  • O(3) .N(2) .N(3) planes is 22.4°, and 4.9° between the O(2) .O(5) . (OW1) and the O(3) .N(2) .N(3).
  • the three planes are parallel in the regular tetradecahedron.
  • the GdL(16) chelate forms a less distorted coordination geometry.
  • Example 2 The filtrate from Example 1 was concentrated in a rotary evaporator, and the resulting viscous solution was mixed with a large amount of THF. The colorless solid that precipitated was the 24-membered ligand. The product was collected on a glass filter, washed with THF and dried in vacuum overnight. The yield was 1.2 g.
  • the cobalt (II) complex of L(24) was obtained by the reaction of 81 mg of L(24)H 4 and 40 mg of cobalt (II) carbonate (from Alfa Products) in 10 ml of water,
  • Example 6 0.4 grams of the ligand produced in Example 6 was suspended in a small amount of water and 0.2 g of
  • gadolinium (III) carbonate supplied from Rare Earth Products
  • the resulting mixture was heated at ca. 40°C with stirring, overnight.
  • the product was extracted with water at ca. 40°C.
  • Gd(III) L(15).8H 2 O was obtained as colorless crystals.
  • the corresponding yttrium(III) complex, YL(15).8H 2 O was obtained in a similar manner by using yttrium(III) carbonate (from Aldrich Chemical Co).
  • Hydrogen atoms associated with the water molecules were located from the Fourier synthesis while other hydrogen atoms were placed at calculated positions.
  • a colorless crystal from example 10 with approximate dimensions of 0.38 ⁇ 0.35 ⁇ 0.22 mm was sealed in a glass capillary.
  • the data collection was performed with monochromated Mo K ⁇ ( ⁇ - 0.71073 A) on an Enraf-Nonius CAD4 diffractometer.
  • DMF dry dimethylformamide
  • Anisotropically refined atoms are given in the form of the
  • aO(4') carboxylato oxygen from the adjacent metal chelate.
  • O(1)-Pb-O(2) 60.4 (1) Pb-N(1)-C(10) 104.2 (3) O(1)-Pb-O(3) 129.1 (1) C(2)-N(1)-C(3) 111.7 (4) O(1)-Pb-O(4') 123.7 (1) C(2)-N(1)-C(10) 110.6 (4) O(l)-Pb-O(5) 138.3 (1) C(3)-N(1)-C(10) 109.8 (4) TABLE 8 CONT'D O(1)-Pb-O(wl) 80.1 (1) Pb-N(2)-C(4) 109. 4 (3)O(1)-Pb-N(1) 64.8 (1) Pb-N(2)-C(5) 110.
  • Anisotropic atoms are given in the form of:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Novel macrocyclic ligands with pendant carboxylic acid groups and their corresponding novel metal complexes are disclosed. Such metal complexes can be used for the enhancement imaging techniques.

Description

METAL COMPLEXES FORMED WITH MACROCYCLIC LIGANDS FOR
USE IN IMAGING TECHNIQUES
Cross-Reference To Related Application
The present application is a continuation-in-part of U.S. Patent Application No. 07/896,118 filed June 10, 1992.
Background of the Invention
The present invention relates to the field of macrocyclic ligands and their corresponding metal
complexes. More particularly, the invention relates to novel macrocyclic ligands with pendant carboxylic acid groups and their corresponding metal complexes which are useful in imaging techniques such as Magnetic Resonance Imaging (MRI), X-ray Contrast Imaging, Positron Emission Tomography (PET), and Single Photo Emission Computer Tomography (SPECT). If the ligands are complexed with a radioisotope and bound to a monoclonal antibody, they can be used in immuno-imaging and immuno-therapy.
In imaging techniques, in order to obtain a better contrast in the picture, nonradioactive or radioactive metals such as gadolinium or yttrium 90 are used.
Contrast enhancers are often needed when dealing with living subjects so that one can distinguish tissues which are histologically dissimilar but magnetically similar.
A problem arises because often these nonradioactive and radioactive metals are toxic to living subjects.
Therefore, it is desirable to incorporate the metals in a compound that will serve as a contrast agent, and at the same time, pass through the living subject and be excreted without releasing the metal. Ligands which can complex with nonradioactive and radioactive metals to form compounds which can serve as non-toxic contrast enhancers are needed.
Ligands which can complex with radioactive metals are also needed in the immuno-imaging and immuno-therapy fields. To be useful in these areas the macrocyclic ligand must be able to bind a radioisotope and also link to a monoclonal antibody. First, the macrocyclic ligand is functionalized, for example with a pendant aminoalkyl group and then linked by a bifunctional linker molecule to amino acid residues on a monoclonal antibody. These ligands can be directed with great selectivity to specific targeted sites in a living subject. This selectivity is achieved by using a monoclonal antibody that binds strongly to antigens that are associated with the targeted sites.
Summary of the Invention
Briefly stated, the present invention encompasses various macrocyclic ligands, their corresponding metal complexes, methods of using the complexes in imaging techniques and a process for synthesizing the ligands.
In accordance with one aspect of the invention, a macrocyclic ligand according to the following formula is provided:
Figure imgf000004_0001
wherein A is selected from the group consisting of:
-(CH2)x
-(CH2)x-NR1- (CH2)y-
-(CH2)x-NR2-(CH2)y-NR3-(CH2)z-; B is selected from the group consisting of:
- ( CH2) v-
Figure imgf000005_0001
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as either m or n;
and R1, R2, R3 is H or any alkyl group.
In accordance with another aspect of the invention, a macrocyclic ligand according to the following formula is provided:
Figure imgf000005_0002
wherein A is selected from the group consisting of
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
- (CH2)x-NR2-(CH2)y-NR3-(CH2)z-;
B is selected from the group consisting of
- (CH2) v-
Figure imgf000005_0003
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n; and R1, R2, R3 is H or any alkyl group.
In accordance with still another aspect of the invention, a macrocyclic ligand according to the following formula is provided:
Figure imgf000006_0001
wherein A is selected from the group consisting of:
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
- (CH2)x-NR2-(CH2)y-NR3-(CH2)z-;
B is selected from the group consisting of:
-(CH2)v-
Figure imgf000006_0002
C is selected from the group consisting of:
- ( CH2) v-
Figure imgf000006_0003
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, or 4;
w is selected to be the same as m or n; and
R1, R2, R3 is H or any alkyl group In accordance with yet another aspect of the invention a macrocyclic ligand having the formula is provided:
Figure imgf000007_0001
In accordance with still another aspect of the invention a macrocyclic ligand having the following formula is provided:
Figure imgf000007_0002
In accordance with yet another aspect of the invention a macrocyclic ligand having the following formula is provided:
Figure imgf000007_0003
In accordance with still another aspect of the invention a macrocyclic ligand having the following formula is provided:
Figure imgf000008_0001
In accordance with yet another aspect of the invention a macrocyclic ligand having the following formula is provided:
Figure imgf000008_0002
In accordance with still another aspect of the invention a metal selected from the group consisting of any metal ion in the +1, +2, +3 or +4 oxidation state is complexed with a macrocyclic ligand having the formula:
Figure imgf000008_0003
wherein A is selected from the group consisting of:
-(CH2)x- -(CH2)x-NR1-(CH2)y-
- (CH2)x-NR2-(CH2)y-NR3-(CH2)z-; wherein B is selected from the group consisting of:
-(CH2)v-
Figure imgf000009_0001
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n; and
R1, R2, R3 is H or any alkyl group.
In accordance with still another aspect of the invention a metal selected from the group consisting of any metal ion in the +1, +2, +3 or +4 oxidation state is complexed with a macrocyclic ligand having the formula:
Figure imgf000009_0002
wherein A is selected from the group consisting of:
-(CH2)x- -(CH2)x-NR1-(CH2)y-
- (CH2)x-NR2-(CH2)y-NR3-(CH2)z-; B is selected from the group consisting of:
-(CH2)v-
Figure imgf000010_0001
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n; and
R1, R2, R3 is H or any alkyl group.
In accordance with yet another aspect of the invention, a method for enhancing contrast in imaging techniques used on living subjects is provided. The method includes administering internally to the subject an effective amount of a contrast agent. The contrast agent comprises a complex of a metal selected from the group consisting of any metal ion that is in the +1, +2, +3 or +4 oxidation state and a macrocyclic ligand having the formula:
Figure imgf000010_0002
wherein A is selected from the group consisting of:
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
-(CH2)x-NR2-(CH2)y-NR3-(CH2)z-; B is selected from the group consisting of:
-(CH2)v-
Figure imgf000011_0001
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n; and
R1, R2, R3 is H or any alkyl group.
In accordance with yet another aspect of the invention, a method for enhancing contrast in imaging techniques used on living subjects is provided. The method includes administering internally to the subject an effective amount of a contrast agent. The contrast agent comprises a complex of a metal selected from the group consisting of any metal ion that is in the +1, +2, +3 or +4 oxidation state and a macrocyclic ligand having the formula:
Figure imgf000011_0002
wherein A is selected from the group consisting of:
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
-(CH2)x-NR2-(CH2)y-NR3-(CH2)z-; B is selected from the group consisting of:
- (CH2) v-
Figure imgf000012_0001
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n; and
R1, R1, R2 is H or any alkyl group
In accordance with yet another aspect of the
invention, a method for synthesizing macrocyclic ligands with pendant carboxylic acid groups is provided.
The present invention, together with its attendant objects and advantages, will be best understood with reference to the detailed description below read in conjunction with the accompanying drawings.
Brief Description of the Drawings
FIGURE 1 shows the molecular structure of a
preferred ligand-metal complex of the present invention.
FIGURE 2 shows the crystal packing in a unit cell of the structure of FIGURE 1.
FIGURE 3 shows the molecular structure of a
preferred ligand-metal complex of the present invention.
FIGURE 4 shows the crystal packing in a unit cell of the structure of FIGURE 3.
FIGURE 5 shows the stereoscopic view of a preferred ligand-metal complex of the present invention.
FIGURE 6 shows the crystal packing in a unit cell of the structure of FIGURE 5.
FIGURE 7 shows the stereoscopic view of the
coordination geometry around the metal of the complex of FIGURE 5. FIGURE 8 shows the molecular structure of a
preferred ligand-metal complex of the present invention.
FIGURE 9 shows the tetradecahedron around the metal of the complex of FIGURE 8.
FIGURE 10 shows the structure of a preferred ligand-metal complex of the present invention.
FIGURE 11 shows the tetradecahedron around the metal of the complex of FIGURE 10.
Detailed Description
of the Preferred Embodiments
Macrocyclic ligands with pendant carboxylic acid groups can be prepared by condensation reactions between a polyalkylpolyaminopolycarboxylic dianhydride and a alkylpolyamine or a polyalkylpolyamine. The reaction occurs in a single step and the product is obtained in relatively high yield without the use of any template metal ions.
The metal complexes of these ligands will be formed readily, especially if the ligand has the same number of displaceable protons as the charge on the metal ion. The metal complexes of these ligands have unusual structures because the metal ions are coordinated not only to the nitrogen donors, but also to the pendant carboxylic acid groups.
When the ligands of the present invention are complexed with a radioactive or non-radioactive metal, the complexes are useful in imaging techniques such as Magnetic Resonance Imaging (MRI), X-Ray Contrast Imaging, Positron Emission Tomography (PET), Single Photo Emission Computer Tomography (SPECT) and Dual X-Ray Absorptiometry (DEXA).
When the ligands of the present invention are complexed with a radioisotope and a targeting molecule such as a monoclonal antibody or a fragment of an
antibody, the complexes are useful in immuno-therapy and immuno-imaging. Any metal ion having a +1, +2, +3 or +4 oxidation number can be used to form a complex with the ligands of the present invention. The preferred metals are
copper(II), lead(II), manganese (II), gadolinium(III), yttrium (III) iron (III) and cobalt (II).
In accordance with one embodiment of the invention macrocyclic ligands of the following formula are
provided:
Figure imgf000014_0001
wherein A is selected from the group consisting of:
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
-(CH2)x-NR2-(CH2)y-NR3-(CH2)z-;
Bz is selected from the group consisting of:
- (CH2) v-
Figure imgf000014_0002
wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w can be either m or n;
R1, R2, R3 is H or any alkyl group. Preferably, A = (CH2)x
and B= (CH2)v or
Figure imgf000015_0001
Most preferably
m = 1, A = (CH2)x, B = (CH2)v, v = 2 and
x = 2. This provides a 12-membered ligand with two pendant carboxylic acid groups, which is denoted as L(12).
Also most preferably
m = 1, A = (CH2)x, B = (CH2)v, x = 3 and
v = 2. This provides a 13-membered ligand with two pendant carboxylic acid groups, which is denoted as L(13).
Also most preferably
A=(CH2)x,
Figure imgf000015_0002
and m=1, x=2, v=2, t=2, and w=1.
This provides a 15-membered ligand with three pendant carboxylic acid groups, which is denoted as L(15).
Also most preferably in this aspect
A=(CH2)x,
Figure imgf000015_0003
and m = 1, x = 3, v = 2, w = 1 and t = 2.
This provides a 16-membered ligand with three pendant acetate groups, denoted as L(16). In accordance with a second aspect of the invention, macrocyclic ligands of the following formula are
provided:
Figure imgf000016_0001
wherein A is selected from the group consisting of
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
-(CH2)x-NR2-(CH2)y-NR3-(CH2)z-;
B is selected from the group consisting of
- ( CH2) v-
Figure imgf000016_0002
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n;
and R1, R2, R3 is H or any alkyl group.
Preferably
A = (CH2)x and B = (CH2)v.
Most preferably, m = 1, A = (CH2)x,
B = (CH2)v, x = 2 and v = 2.
This provides a 24-membered ligand with 4 pendant carboxylic acid groups, which is denoted as L(24). In accordance with a third aspect of the invention, macrocyclic ligands of the following formula are
provided:
Figure imgf000017_0001
wherein A is selected from the group consisting of:
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
-(CH2)x-NR2-(CH2)y-NR3-(CH2)z-;
B is selected from the group consisting of:
-(CH2)v-
Figure imgf000017_0002
C is selected from the group consisting of:
-(CH2)v-
Figure imgf000017_0003
and wherein m, n, t, u, v, w, x, y, z are independentlt selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n; and
R1, R2, R3 Is H or any alkyl group. Figures 1-11 are various views of the presently preferred metal complexes of the presently preferred macrocyclic ligands of the instant invention.
Figure 1 shows the molecular structure of
CuL(12).4H2O and Figure 2 shows the crystal packing in the unit cell of CuL (12).4H2O. Table 1 summaries the crystal data. Tables 2 and 3 show the selected bond distances and bond angles. Table 4 shows the positional parameters of the non-hydrogen atoms. L(12) consists of a 12-membered ring with amide bonds and contains two pendant carboxylic acid groups. Each copper atom is coordinated to an amine nitrogen atom Nl (Cu-N=2.088 Å), an amide oxygen atom 05 (Cu-O=1.988 Å), a carboxylato oxygen atom 03 (Cu-O=1.996 Å) and another carboxylato oxygen atom 01 that belongs to the neighboring metal chelate (Cu-O=1.936 Å). In addition to these four atoms which form a plane around copper, an amine nitrogen atom N2 and a
carboxylato oxygen atom 02 are weakly coordinated to copper with Cu-N=2.485 Å and Cu-O=2.334 A and form an elongated octahedron around the copper. One of the amide groups is not coordinated to the metal ion. The 12-membered ring is too small to involve the metal ion inside its macrocyclic cavity. Water molecules are hydrogen-bonded to each other and are not coordinated to copper. One of the features of the structure is that one of the acetate groups is coordinated to two copper atoms forming a one-dimensional -Cu-O-C-O=Cu- chain.
Figure 3 shows the structure and Figure 4 shows the crystal packing in the unit cell of Mn2L(24).8H2O.
Table 5 shows the positional parameters of the non- hydrogen atoms. The bond distances and the bond angles are collected in Tables 6 and 7. L(24) has a 24-membered ring and four pendant carboxylic acid groups. Each ligand is coordinated to two manganese ions. The
resulting manganese chelate molecule has C2 symmetry, the symmetry axis of which coincides with the crystal C2 axis and passes perpendicular to the averaged molecular plane of the macrocyclic ring. The manganese atoms within a chelate molecule are, therefore, crystallographically equivalent to each other. Each metal atom is coordinated to four oxygen atoms and two nitrogen atoms with bond distances of 2.111-2.445 A; two oxygen atoms 01 and 03 from two carboxylato groups (Mn-O=2.184 A), a water molecule (denoted OW1, Mn-O=2.137 A) and two amine nitrogen atoms N1 and N2 (Mn-N1=2.445 and Mn-N2=2.358 A). The Mn-O distances of 2.111-2.212 A are significantly shorter than the Mn-N distance of 2.358-2.445 A. An additional weak bond is formed between a Mn atom and an amide oxygen atom 06 with a distance of 2.686 Å. Thus, a distorted seven-coordination geometry is established around the metal atoms.
The 24-membered macrocyclic ligand was obtained as an amorphous powder, whereas its Mn(II) complex was obtained in a crystalline form. Chelate formation with metal ions makes the ring rigid and results in a well- defined configuration of the chelate ring. The
structural integrity of the metal chelate rings leads to the formation of crystals of the metal chelate.
Extensive hydrogen bonding occurs in the crystal lattice structure and defines the arrangement of the metal chelate molecules in the crystal. A water molecule (OW2) occupies a special position on the crystal C2 axis that coincides with the C2 axis of the metal chelate ring.
This water molecule forms strong hydrogen bonds with two water molecules (OW1) coordinated to Mn and also with two amide oxygen atoms that are weakly bonded to Mn. These hydrogen bonds firmly link the two Mn ions within a chelate ring and define the molecular structure of the metal chelate.
Figure 5 shows a stereoscopic view of PbL(13). The crystal packing diagram is shown in Figure 6. Figure 7 shows a stereoscopic view of the coordination geometry around the Pb(II) ion. Table 8 shows the bond distances and angles. Table 9 shows the fractional coordinates and equivalent isotropic temperature factors. L(13) forms a non-ionic neutral Pb(II) complex. A ligand molecule is coordinated to a Pb(II) ion with two carboxylato oxygen atoms, O(3) and O(5), two amide oxygen atoms, O(1) and O(2), and two amine nitrogen atoms, N(1) and N(2). All these donor atoms are located in half the coordination sphere because the ligand is unable to occupy all the positions in the coordination sphere of the metal ion. The remaining coordination positions are occupied by a water oxygen atom (OW1) and a carboxylato oxygen atom O(4') from the adjacent metal chelate. If the very long Pb-O(4') distance of 3.223 Å is considered to be a Pb-0 bond, the resulting molecule is a binuclear chelate. The water molecule (OW1), that is coordinated to the Pb(II) ion forms a hydrogen bond with O(3') of the adjacent metal chelate, thereby stabilizing the binuclear chelate. Other hydrogen bonds with the O-O distance less than 2.9 Å are found for OW1-O(6), OW2-O(4) and OW3-O(6) atomic pairs.
The coordination geometry around the Pb(II) ion that includes the two distant atoms O(2) and O(4) can be described as a highly distorted dodecahedron. For example, the O(4)-O(5) distance (3.836 Å) in the
polyhedron is much longer than the O(1)-N(l) distance (2.803 Å); these distances would be equal in a regular dodecahedron with D2d symmetry. In addition, the O(2)-OW1 and O(3)-N(2) distances are quite different from each other: O(2)-OW1=5.017Å and O(3)-N(2)=3.358Å. This extreme distortion is caused by the nature of the ligand. The -C-CO-N-C- atoms in each amide group are on the same plane; the largest deviation from the averaged plane is 0.09Å for the amide N(4)HC (2) O(1), and 0.014Å for
N(3)HC(6) O(2). This planarity makes the macrocyclic ring inflexible. Moreover, the macrocycle cannot extend itself to occupy all the coordination positions around the Pb(II) ion. These geometrical constraints of the ligand and the coordination of the amide oxygen atoms result in novel coordination geometry around the Pb(II) atom.
Figure 8 shows the stereoview of GdL (15).8H20, the atoms are shown at a 20% probability level. Figure 9 shows the tetradecahedron around the Gd ion in Gd
L(15).8H2O. Table 10 summarizes the crystal data.
Table 11 shows the positional parameters of GdL (15).8H2O. Table 12 shows the positional parameters of YL(15).8H2O. Table 13 shows the M-X and C-O bond distances. Table 14 shows the bond angles. The X-ray results show that the 15-membered macrocyclic ligand has three pendant
carboxylic acid groups and that the ligand forms a neutral non- ionic metal chelate. Each ligand molecule is coordinated to two Gd ions and each metal ion has nine coordination bonds with: two carboxylato oxygen atoms O(3) and O(5), an amide oxygen atom O(1) and two amine nitrogen atoms N(l) and N(2) from one ligand molecule; a carboxylato oxygen atom O(7), an amide oxygen atom O(2) and an amine nitrogen atom N(3) from the second ligand molecule and a water oxygen atom (OW1). Two metal ions are located between two ligand molecules, forming a binuclear metal chelate, in which the averaged molecular planes of the two macrocyclic rings are parallel to each other. The resulting metal chelate molecules have an inversion center with the result that the two metal ions are crystallographically equivalent to each other.
Figure 10 shows the structure of GdL (16).4H2O, the atoms are shown at a 50% probability level. Figure 11 shows the tetradecahedron around the Gd ion. Table 10 summarizes the crystal data. Table 15 shows the
positional parameters for GdL(16).4H2O. Table 16 shows the bond distances and angles. Each metal ion has nine coordination bonds with: two amide oxygen atoms O(1) and O(2), three carboxylato oxygen atoms O(3), O(5) and O(7) and three amine nitrogen atoms N(1), N(2) and N(3) from a single ligand molecule, and a water oxygen atom (OW1). Therefore, the ligand molecule occupies all the coordination sites around the Gd(II) ion jointly with a water molecule.
The Gd(III) complexes of L(15) and L(16) both have M-O bond distances significantly shorter than M-N
distances, a water molecule is strongly coordinated to a metal ion, and the amide oxygen atoms are coordinated to metal ions, whereas none of the amide nitrogen atoms is bonded to a metal ion.
However, there are significant differences between the structures of the GdL(15) and GdL(16) complexes.
First the L(15) ligand is coordinated to two Gd(III) ions resulting in a binuclear chelate, whereas the L(16) ligand is coordinated to single metal ion and forms a mononuclear molecule. The coordination geometries in both Gd(III) chelates are described as tricapped trigonal prisms. However, the sequences of the coordinated atoms in the tetradecahedrons are quite different from each other. The tetradecahedron in the GdL(15) chelate is highly distorted from the ideal D3h geometry. The
dihedral angle between the O(1).N(1).O(7) and the
O(3) .N(2) .N(3) planes is 22.4°, and 4.9° between the O(2) .O(5) . (OW1) and the O(3) .N(2) .N(3). The three planes are parallel in the regular tetradecahedron. The
corresponding dihedral angles in the GdL (16) chelate are 5.6° between the O(5) .O(7) .N(2) and the N(1) .N(3) .OW1 planes and 7.3° between the O(1) .O(2) .O(3) and the
N(1) .N(3) .OW1 planes. The GdL(16) chelate forms a less distorted coordination geometry.
Examples
The following examples are provided by way of explanation and illustration. As such, these examples are not to be viewed as limiting the scope of the invention as defined by the appended claims.
Example 1-Synthesis of L(12)H2
In a three-neck flask assembled with a condenser, a dropping funnel and a nitrogen-inlet tube, 2.05g (8.0 mmol) of ethylenediaminetetraacetic dianhydride (from Aldrich Chemical Co.) was suspended in 350 ml of dry dimethylformamide (DMF) with stirring under a nitrogen atmosphere. To the suspension was added dropwise a DMF solution (50 ml) containing 0.48g (8.0 mmol) of
ethylenediamine (supplied from Aldrich Chemical Co.) through the dropping funnel for a period of 2 hours. The resulting reaction mixture was heated at 60° for 3 hours and left to stand at room temperature overnight. The precipitate formed was removed by filtration. The filtrate was concentrated by the use of a rotary
evaporator at a temperature below 60°C and 10 ml of water was added to the resulting viscous liquid. The finely divided solid that was formed was separated by
filtration, washed with tetrahydrofuran (THF) and dried in vacuum; this product was L(12)H2. Yield: 0.6g. Anal. Calcd. for C12H20N4O6: C,45.56; H,6.37; N,17.71%. Found: C45.23; H.6.31; N, 16.97%.
Example 2-Synthesis of Metal Complex of L(12)
L(12)H2 from Example 1 was suspended in water and was reacted with a large excess of copper (II)
hydroxycarbonate (from J.T.Baker Chemical Co.) at ca.
45°C with stirring overnight. Unreacted solids were removed by filtration. Evaporation of the solvent at ca. 40°C yielded a vitreous solid, which was repeatedly purified by crystallization from water. Light blue needle-like crystals suitable for an X-ray crystal analysis were grown from an aqueous solution by slow evaporation.
Example 3 -Synthesis of L(24)H4
The filtrate from Example 1 was concentrated in a rotary evaporator, and the resulting viscous solution was mixed with a large amount of THF. The colorless solid that precipitated was the 24-membered ligand. The product was collected on a glass filter, washed with THF and dried in vacuum overnight. The yield was 1.2 g. The Anal. Calcd. for C24H40N8O12.H2O: C,44.30: H,6.51; N, 17.22%. Found: C,44.67; H,6.89; N,16.69%.
Example 4-Synthesis of Metal Complex of L(24)
L(24)H4 from Example 3 was suspended in water and reacted with manganese (II) carbonate (from J.T.Baker Chemical Co.) in the mole ratio of 1:2 at 45°C with stirring overnight. The unreacted solids were removed by filtration. The filtrate was concentrated at 45°C. When the resulting solution was mixed with a large amount of ethanol, a colorless solid was obtained. Repeated recrystallization of the product from water by slow evaporation yielded needle-like colorless crystals.
The cobalt (II) complex of L(24) was obtained by the reaction of 81 mg of L(24)H4 and 40 mg of cobalt (II) carbonate (from Alfa Products) in 10 ml of water,
followed by filtration and concentration. In two weeks, pink needle-like crystals suitable for an X-ray crystal analysis were grown from an aqueous solution.
Example 5-X-Ray Crystal Analyses of Metal Complexes of L(12) and L(24)
Data collection was performed on a Syntex P21 diffractometer with Crystal Logic automatic system. The cell parameters were determined using 25 reflections in the range of 20<2Θ<30°. Crystal data are summarized in
Table 1. The Θ-2Θ scan method was used. For CuL(12).4H2O,
2368 reflections were collected in the scan range
0<2Θ≤55°; 2343 reflections were unique. The 1807
reflections with I>3σI were used in the refinements. For
Mn2L(24).8H2O, 5592 reflections were collected in the range of 0<2Θ≤50° of which 1804 were unique. The 1510 reflections with I>3σI were used for refinements. Metal atoms were located by direct methods and the remaining atoms were placed at calculated positions and were included in the refinement. All calculations were performed on a VAX computer with a SPD/VAX program.
Example 6-Synthesis of L(15)H3
To 2.45 g of diethylenetriaminepentaacetic
dianhydride (from Aldrich Chemical Co.) that was
suspended in 350 ml of dry dimethylformamide (DMF) was added dropwise a 50 ml of DMF containing 0.413 g of ethylenediamine (from Aldrich Chemical Co.) in a period of 4 hours with vigorous stirring under a nitrogen atmosphere. The reaction mixture was heated at 50°C for 3 hours and then left to stand for ca. 16 hours at room temperature. The precipitate formed was removed by filtration. Concentration of the filtrate at a
temperature below 40°C resulted in the formation of a light yellow solid and a viscous liquid. To this
reaction mixture, a small amount of water was added to dissolve the solid. When the resulting solution was mixed with tetrahydrofuran, the ligand was obtained as a colorless solid. The yield was 1.9 g. The Anal. Calc. for C16H27N5O8.1.5H2O is C,43.24; H,6.80 and N,15.76%. The actual percentages were C,43.15; H,6.79; and N, 15.42%.
Example 7-Synthesis of Metal Complexes of L(15)
0.4 grams of the ligand produced in Example 6 was suspended in a small amount of water and 0.2 g of
gadolinium (III) carbonate (supplied from Rare Earth Products) was added with stirring. The resulting mixture was heated at ca. 40°C with stirring, overnight. From the resulting solid, the product was extracted with water at ca. 40°C. By evaporation of water, Gd(III) L(15).8H2O was obtained as colorless crystals. The corresponding yttrium(III) complex, YL(15).8H2O, was obtained in a similar manner by using yttrium(III) carbonate (from Aldrich Chemical Co). Example 8-X-ray Analysis
A crystal of each complex was sealed in a glass capillary together with the mother liquor for X-ray analyses; the crystals were found to readily effloresce. Table 10 summarizes the crystal data and the data
collections of the Gd(III) and Y(III) complexes. An empirical absorption correction based on a series of φ scans was applied to the data. Each structure was solved by the Patterson heavy-atom method, which revealed the position of the metal atom. The remaining atoms were located in succeeding difference Fourier syntheses.
Hydrogen atoms associated with the water molecules were located from the Fourier synthesis while other hydrogen atoms were placed at calculated positions.
Example 9 -Synthesis of L(13)H2
To 2.0 g (8 mmol) of ethylenediaminetetraacetic dianhydride (from Aldrich Chemical Co.) suspended in 350 ml of dry dimethylformamide (DMF) was added dropwise a DMF solution (50 ml) containing 0.58 g (8 mmol) of 1,3-diaminopropane (from Aldrich Chemical Co.) with stirring under a nitrogen atmosphere for a period of 2 hours. The resulting reaction mixture was heated at 60°C for 3 hours and left to stand at room temperature overnight. The precipitate formed was removed by filtration. The filtrate was concentrated by the use of a rotary
evaporator at a temperature below 50°C, and the resulting viscous solution was mixed with a large amount of THF. The colorless solid that was formed was separated by filtration, washed with THF, and dried in vacuum. Anal. Calcd. for C13H22N4O6: C,47.27; H,6.67; N, 16.97. Found: C47.56; H,6.76; N, 16.91.
Example 10-Synthesis of Metal Complex of L(13)
The ligand L(13)H2 produced in example 9 was
suspended in a small amount of water and was added to an equivalent amount of lead (II) carbonate (from Mallinckrodt Chemical Works) at 45°C with stirring overnight. The unreacted solid was removed by
filtration. When ethanol was added to the filtrate, the lead (II) complex was precipitated as a colorless solid. A block crystal suitable for X-ray analysis was grown from an aqueous solution by slow evaporation.
Example 11-X-ray Crystal Analysis of Metal Complex of L(13)
A colorless crystal from example 10 with approximate dimensions of 0.38 × 0.35 × 0.22 mm was sealed in a glass capillary. The data collection was performed with monochromated Mo Kα (λ - 0.71073 A) on an Enraf-Nonius CAD4 diffractometer. The cell constants were determined from 25 reflections in the range 26 < 20 < 36°. From the systematic absences (hOℓ, ℓ - 2n + 1; OkO, k = 2n + 1) the space group was determined to be P21/c (No. 14). The data were collected using w-20 scan method at a rate of 1-7° min-1 in the range 0 < 20 ≤ 50° (h-0 to 10; k = 0 to 27; ℓ↼ =11 to 11): (sinΘ)/λ≤ 0.5940 Å-1. Three standard reflections were monitored every 60 min, and were
constant within experimental error. A total of 3567 reflections were collected, 3245 of which were unique and not systematically absent. μ=92.6 cm-1. An empirical absorption correction based on a series of Ψ-scans were applied to the data. Relative transmission coefficients ranged from 0.552 to 0.998 with an average value of
0.852. The structure was solved by the Patterson heavy-atom method which revealed the position of the Pb atom. The remaining atoms were located in succeeding difference Fourier syntheses. Hydrogen atoms were included in the refinement but constrained to ride on the atom to which they were bonded. Non-hydrogen atoms were
anisotropically refined. The full-matrix least-squares refinements were carried out using 2829 reflection with I > 3σ : where Σw(|Fo| - |Fc|)2 was minimized; w was
calculated from 4Fo 22(Fo 2). Scattering factors used were from Cromer and Waber (1974). The anomalous dispersion effects were included in Fc, the values for Δf' and Δf" were those of Cromer (1974). The final agreement factors for 244 variables were: R=∑|Fo - Fc|/ΣFo = 0.026 and Rw = [Σw(Fo - Fc)2/ΣwFo 2]1/2 = 0.038. The standard derivation of an observation of unit weight was 1.57. The ratio of Δmax/σ was less than 0.01. The highest peak in the final difference Fourier was found near the Pb atom with a height of 1.1 (1)e- Å-3; the minimum negative peak had a height of -0.3 (1) e- Å-3. All calculations were performed on a VAX computer with a MolEN (Enraf-Nonius) program.
Example 12-Synthesis of L(16)H3
To 2.45 g of diethylenediaminepentaacetic
dianhydride (from Aldrich Chemical Co.) that was
suspended in 350 mL of dry dimethylformamide (DMF) was added dropwise a DMF solution (50 mL) containing
propylenendiamine (from Aldrich Chemical Co.) for a period of 4 hours with vigorous stirring under a nitrogen atmosphere. The reaction mixture was heated at 50°C for 3 hours and then left to stand for ca. 16 hours at room temperature. The precipitate formed was removed by filtration. The filtrate was concentrated and purified by precipitation from a concentrated aqueous solution by the addition of ethanol. Anal. Calcd. for
C17H29N5O8.C2H50H.2H2O: C,44.43; H,7.65; N, 13.64. Found:
C,45.05; H,7.21; N, 12.97.
Example 13-Metal Complex of L(16)
To 0.4 g of L(16) suspended in a small amount of water, 0.2 g of gadolinium(III) carbonate (supplied from Rare Earth Products) was added with stirring. The resulting mixture was heated at ca. 40°C with stirring overnight. The product was purified by adding ethanol to the aqueous solution. Single crystals suitable for X-ray analyses were obtained as a tetrahydrate by diffusion of acetone into an aqueous solution of the complex in a narrow bore tube.
TABLE 1
Summary of Crystal Data for CuL(12) ·4H2O(I) and Mn2L(24) ·8H2O (II) complex I II
empirical formula CuC12H26N4O10 Mn2C24H52N8O20
F.W. 449.90 882.60
T/°C 23 23
λ/Å (monochromated 0.71073 1 0.71073
Mo Ka)
F(000) 940 1386
crystal 0.30×0. 18×0 .17 0.48×0.37×0.25 dimensions/mm
space group orthorhombic hexagonal
P212121 (No. 19) P62 (No.171)a
Cell parameters
a/Å 10.070 (1) 18.072 (3)
b/Å 18.832 (2) 18.072 (3)
c/Å 9.425 (1) 10.195 (2)
V/Å3 1787.3 (6) 2884 (2)
Z 4 3
dcalcd/g cm-3 1.67 1.56
μ/cm-1 12.8 7.2
R(Fo) 0.040 0.036
Rw(Fo 2) 0.050 0.055
aRepresented by one of the space groups of a chiral pair (P62 and P64) TABLE 2
Selected Bond Distances (Å) in CuL(12)·4H2O.
Atom 1 Atom 2 Distance Atom 1 Atom 2 Distance
Cu O1 1.936(4) 01 C4 1.277(6)
Cu O2 2.334(3) 02 C4 1.233(6)
Cu O3 1.996(4) 03 C6 1.274(6)
Cu O5 1.988(4) 04 C6 1.248(6)
Cu N1 2.088(4) 05 C8 1.254(6)
Cu N2 2.485(4) 06 C10 1.249(8)
TABLE 3 Selected Bond Angles (in Degrees) in CuL(12)·4H2·.
Atom Atom Atom Angle Atom Atom Atom Angle 1 2 3 1 2 3
01 Cu O2 99.8(1) O2 Cu N2 142.9(1)
01 Cu O3 91.3(2) O3 Cu O5 177.1(2)
01 Cu O5 88.6(2) O3 Cu N1 97.7(2)
01 Cu N1 168.7(2) O3 Cu N2 74.5(1)
01 Cu N2 108.5(1) O5 Cu N1 82.7(2)
02 Cu O3 81.4(1) O5 Cu N2 102.7(1)
02 Cu O5 101.5(1) N1 Cu N2 80.7(1)
02 Cu N1 75.0(1)
TABLE 4
Positional Parameters and Their Estimated Standard Deviations of Non-hydrogen Atoms of CuL (12)·4H2O.
Atom X y z B (Å2)
Cu 0.49178(5) 0.23571(3) 0.57602(6) 1.557(8)
O1 0.4096(3) 0.2862(2) 0.4202(4) 2.26(7)
O2 0.2060(3) 0.2777(2) 0.5147(4) 2.05(7)
O3 0.0711(4) 0.1746(2) 0.3494(4) 2.17(7)
O4 0.0181(4) 0.0660(2) 0.2751(5) 3.42(9)
O5 -0.0955(4) 0.3526(2) 0.4923(4) 2.17(7)
O6 -0.3238(5) 0.3716(3) 0.0667(5) 4.6(1)
N1 0.0861(4) 0.3346(2) 0.854(4) 1.51(7)
N2 -0.1333(4) 0.2370(2) 0.2034(5) 1.84(7)
N3 -0.1356(5) 0.4626(2) 0.4059(5) 2.67(9)
N4 -0.3233(4) 0.3571(3) 0.3047(5) 2.54(9)
C1 0.0183(5) 0.3370(3) 0.1451(5) 2.2(1)
C2 -0.0338(5) 0.2642(3) 0.1021(5) 2.22(9)
C3 0.2282(4) 0.3136(3) 0.2722(6) 1.85(9)
C4 0.2831(5) 0.2911(3) 0.4166(6) 1.97(9)
C5 -0.1271(6) 0.1585(3) 0.2108(6) 2.6(1)
C6 -0.0028(6) 0.1312(3) 0.2823(5) 2.27(9)
C7 0.0767(5) 0.4048(3) 0.3569(6) 2.1(1)
C8 -0.0598(5) 0.4067(3) 0.4248(6) 2.09(9)
C9 -0.2713(5) 0.2556(3) 0.1593(6) 2.4(1)
C10 -0.3075(5) 0.3344(3) 0.1749(6) 2.5(1)
C11 -0.2743(6) 0.4621(3) 0.4549(7) 3.1(1)
C12 -0.3621(6) 0.4301(3) 0.3404(8) 3.4(1)
OW1 0.6732(7) 0.6359(3) 0.3121(6) 6.6(2)
OW2 0.3457(7) 0.5026(3) 0.5139(8) 7.5(2)
OW3 0.5991(7) 0.9556(4 0.4053(8) 7.9(2)
OW4 0.5758(6) 0.0684(3 0.2318(8) 7.9(2) TABLE 4 CONT' D
.Anisotropically refined atoms are given in the form of the isotropic equivalent displacement parameter defined as:
(4/3) [a2·B(1.1) + b2·B(2,2) + c2·B(3,3) + ab(cos γ)-B(1,2) + ac(cos β)·B(1,3) + bc(cos α)·B(2,3)]
TABLE 5
Positional Parameters and Their Estimated Standard Deviations of Non-hydrogen Atoms of Mn2L(24)·8H·O.
Atom x y z B (Å2)
Mn 0.41960(5) 0.15747(4) 0.311 2.16(1)
O1 0.3105(2) 0.1395(3) 0.1896(4) 3.5(1)
O2 0.2128(2) 0.1761(3) 0.1542(5) 3.39(9)
O3 0.4970(3) 0.2705(2) 0.2046(4) 3.2(1)
O4 0.6163(3) 0.3950(3) 0.1965(5) 4.2(1)
O5 0.3787(2) 0.0524(2) 0.4508(5) 3.28(9)
O6 0.5609(2) 0.1619(2) 0.4042(4) 2.73(8)
N1 0.3103(3) 0.1572(2) 0.4530(5) 2.30(9)
N2 0.4974(2) 0.2622(2) 0.4714(5) 2.12(9)
N3 0.3031(3) -0.0148(2) 0.6286(5) 2.7(1)
N4 0.6172(3) 0.1702(3) 0.6056(5) 2.8(1)
C1 0.3528(3) 0.2167(3) 0.5630(6) 2.6(1)
C2 0.4390(3) 0.2911(3) 0.5200(6) 2.6(1)
C3 0.2592(3) 0.1830(3) 0.3730(6) 3.0(1)
C4 0.2608(3) 0.1639(3) 0.2278(6) 2.7(1)
C5 0.5708(3) 0.3337(3) 0.4047(6) 2.6(1)
C6 0.5599(3) 0.3341(3) 0.2583(6) 2.6(1)
C7 0.2590(3) 0.0681(3) 0.4981(6) 2.7(1)
C8 0.3185(3) 0.0342(3) 0.5249(6) 2.2(1)
C9 0.5280(3) 0.2297(3) 0.5779(6) 2.5(1)
C10 0.5717(3) 0.1843(3) 0.5205(5) 2.1(1)
C11 0.3559(3) -0.0532(3) 0.6582(7) 3.0(1)
C12 0.6679(4) 0.1299(3) 0.5726(8) 3.4(1)
OW1 0.4231(3) 0.0717(2) 0.1705(4) 3.8(1)
OW2 0.000 0.500 0.9678(7) 3.1(1)
OW3 0.1784(3) 0.3009(3) 0.2365(6) 5.1(1)
OW4 0.3423(4) 0.4387(4) 0.2455(6) 5.8(2)
OW5 0.0416(7) 0.0803(7) 0.052(1) 5.0 TABLE 5 CONT'D
When OW5 was refined by assuming a fixed isotropic thermal
parameter, an occupancy of approximately 0.5 was obtained.
Anisotropically refined atoms are given in the form of the
isotropic equivalent displacement parameter defined as:
(4/3) [a 2·B(1.1) + b2·B(2,2) + c2·B(3,3) + ab(cos γ) ·B(1,2) + ac(cosβ)-B(1,3) + bc(cos α) -B(2,3)]
TABLE 6
Selected Bond Distances (A) in Mn2L(24) ·8H2O
Atom 1 Atom 2 Distance Atom 1 Atom 2 Distance
Mn O1 2.212(5) O1 C4 1.244(9)
Mn O3 2.111(4) O2 C4 1.248(8)
Mn O5 2.184(4) O3 C6 1.268(6)
Mn O6 2.686(4) O4 C6 1.235(6)
Mn OW1 2.137(5) O5 C8 1.226(7)
Mn N1 2.445(5) O6 C10 1.237(7)
Mn N2 2.358(4) OW2 O6 2.767(5)
OW1 OW2 2.680(6)
TABLE 7
Selected Bond Angles (in Degrees) in Mn2L(24)·8H2O
Atom 1 Atom Atom Angle Atom Atom Atom Angle
2 3 1 2 3
01 Mn O3 87.9(2) O5 Mn 06 72.6(1)
01 Mn O5 110.4(1) O5 Mn OW1 85.8(2)
01 Mn O6 165.0(2) O5 Mn N1 72.1(2)
01 Mn OW1 82.2(2) O5 Mn N2 93.1(2)
01 Mn N1 70.8(2) O6 Mn OW1 83.4(2)
01 Mn N2 129.5(2) O6 Mn N1 123.2(2)
03 Mn O5 161.7(2) O6 Mn N2 63.7(2)
03 Mn O6 89.6(2) OW1 Mn N1 135.4(1)
03 Mn OW1 96.3(2) OW1 Mn N2 145.6(2)
03 Mn N1 116.8(2) N1 Mn N2 75.5(1)
03 Mn N2 74.9(2)
TABLE 8
Bond distances (Å) and Angles (°)
Pb-O(1)amide 2 585 (3) N(1)-C(2) 1 468 (6) Pb-O(2)amide 2 968 (4) N(1)-C(3) 1 487 (7)
Pb-O(3)carboxylato 2 426 (4) N(1)-C(10) 1 476 (6) Pb-O(5)carboxylato 2 .649 (4) N(2)-C(4) 1 469 (5)
Pb-N(1)amine 2 .644 (3) N(2)-C(5) 1 491 (6) Pb-N(2)amine 2 .594 (4) N(2)-C(12) 1 467 (7) Pb-O(w1)water 2 .614 (4) N(3)-C(7) 1 478 (7) Pb-O(4')a 3 .223 (4) N(4)-C(9) 1 .453 (7)
C(1) -O(1)amide 1 .228 (5) C(1)-C(2) 1 .523 (7)
C(1) -N(4)amide 1 .325 (6) C(3)-C(4) 1 .503 (7) C(6)-O(2)amide 1 .232 (6) C(5)-C(6) 1 .520 (8) C(6) -N(3)amide 1 .320 (6) C(7)-C(8) 1 .509 (7) C(11) -O(3)carboxylato 1 .271 (6) C(8)-C(9) 1 .544 (8) C(11) -O(4)carboxylato 1 .241 (6) C(10)-C(11) 1 .503 (6) C(13) -O(5)carboxylato 1 .265 (9) C(12)-C(13) 1 .525 (8) C(13) -O(6)carboxylato 1 .225 (8)
aO(4'): carboxylato oxygen from the adjacent metal chelate. O(1)-Pb-O(2) 60.4 (1) Pb-N(1)-C(10) 104.2 (3) O(1)-Pb-O(3) 129.1 (1) C(2)-N(1)-C(3) 111.7 (4) O(1)-Pb-O(4') 123.7 (1) C(2)-N(1)-C(10) 110.6 (4) O(l)-Pb-O(5) 138.3 (1) C(3)-N(1)-C(10) 109.8 (4) TABLE 8 CONT'D O(1)-Pb-O(wl) 80.1 (1) Pb-N(2)-C(4) 109. 4 (3)O(1)-Pb-N(1) 64.8 (1) Pb-N(2)-C(5) 110. 3 (3)O(1)-Pb-N(2) 83.8 (1) Pb-N(2)-C(12) 106. 8 (3)O(2)-Pb-O(3) 148.2 (1) C(4)-N(2)-C(5) 110. 4 (4)O(2)-Pb-O(4') 105.47 (9) C(4)-N(2)-C(12) 111. 4 (4)O(2)-Pb-O(5) 81.8 (1) C(5)-N(2)-C(12) 108 .3 (4)O(2)-Pb-O(wl) 127.9 (1) C(6)-N(3)-C(7) 123 .5 (5)O(2)-Pb-N(1) 111.3 (1) C(1)-N(4)-C(9) 123 .3 (4)O(2)-Pb-N(2) 66.1 (1) O(1)-C(1)-N(4) 123 .1 (5)O(3)-Pb-O(4') 92.5 (1) O(1)-C(1)-C(2) 120 .1 (4) O(3)-Pb-O(5) 75.3 (1) N(4)-C(1)-C(2) 116 .8 (4)O(3)-Pb-O(w1) 82.9 (1) N(1)-C(2)-C(1) 111 .5 (4) O(3)-Pb-N(1) 64.6 (1) N(1)-C(3)-C(4) 113 .1 (4) O(3)-Pb-N(2) 83.9 (1) N(2)-C(4)-C(3) 112 .6 (4) O(4')-Pb-O(5) 81.0 (1) N(2)-C(5)-C(6) 110 .3 (4) O(4')-Pb-O(w1) 68.1 (1) O(2)-C(6)-N(3) 125 .6 (5) O(4')-Pb-N(1) 139.2 (1) O(2)-C(6)-C(5) 117 .6 (4)O(4')-Pb-N(2) 144.4 (1) N(3)-C(6)-C(5) 116 .8 (5) O(5)-Pb-O(w1) 141.1 (1) N(3)-C(7)-C(8) 114 .1 (4) O(5)-Pb-N- (1) 120.7 (1) C(7)-C(8)-O(9) 118 .1 (4) O(5)-Pb-N(2) 63.8 (1) N(4)-C(9)-C(8) 116 .1 (5) O(w1)-Pb-N(1) 75.6 (1) N(1)-C(10)-C(11) 113 .3 (4) O(w1)-Pb-N(2) 145.4 (1) O(3)-C(11)-O(4) 123 .6 (4) TABLE 8 CONT'D
N(1)-Pb-N(2) 69.9 (1) O(3)-C(11)-C(10) 118.2 (4)
Pb-O(1)-C(1) 120.4 (3) O(4)-C(11)-C(10) 118.2 (4)
Pb-O(3)-C(11) 118.6 (3) N(2)-C(12)-C(13) 115.9 (5)
Pb-O(5)-C(13) 112.3 (3) O(5)-C(13)-O(6) 126.5 (6)
Pb-N(1)-C(2) 112.3 (3) O(5)-C(13)-C(12) 118.0 (5)
Pb-N(1)-C(3) 108.0 (2) O(6)-C(13)-C(12) 115.4 (6)
Hydrogen bonds
A B C A-B B-C A-C A-B-C
O(w1)-H(w1a)-O(3) 0.954 (4) 1.876 (3) 2.780 (5) 157.0 (3)
O(w1)-H(w1b)-O(6) 0.919 (4) 1.859 (4) 2.703 (5) 151.7 (3)
O(w2)-H(w2b)-O(4) 0.903 (5) 1.871 (4) 2.748 (6) 163.1 (3)
O(w3)-H(w3b)-O(6) 0.882 (6) 2.044 (6) 2.886 (8) 159.1 (4)
TABLE 9
Fractional coordinates and equivalent isotropic temperature factors.
x y z βeq2)
Pb 0.03928 (2) 0.10685 (1) 0.11590 (2) 1.920(4) O(1) 0.2813 (4) 0.1693 (2) 0.2529 (4) 2.71 (8) O(2) 0.0048 (5) 0.2344 (2) 0.1343 (4) 2.89 (8) O(3) -0.0309 (4) 0.0108 (2) 0.1786 (4) 2.60 (8) O(4) 0.0661 (5) -0.0774 (2) 0.2381 (5) 3.66 (9) O(5) -0.2688 (5) 0.1107 (2) 0.0556 (5) 3.5 (1) O(6) -0.4315 (4) 0.0680 (2) 0.1586 (6) 5.5 (1) O(w1) 0.2561 (4) 0.0498 (2) 0.0442 (4) 3.95 (9) O(w2) 0.7075 (5) 0.1595 (2) 0.7453 (5) 5.0 (1) O(w3) 0.4721 (6) 0.0544 (3) 0.8008 (5) 5.6 (1)
N(1) 0.2217 (4) 0.0640 (2) 0.3737 (4) 1.99 (8)
N(2) -0.0599 (4) 0.1398 (2) 0.3341 (4) 1.92 (8)
N(3) 0.1162 (5) 0.2667 (2) 0.3731 (4) 2.50 (9)
N(4) 0.4740 (5) 0.1892 (2) 0.4673 (5) 2.8 (1)
C(1) 0.3725 (5) 0.1537 (2) 0.3744 (5) 2.02 (9)
C(2) 0.3785 (6) 0.0902 (2) 0.4212 (6) 2.4 (1)
C(3) 0.1412 (6) 0.0723 (2) 0.4881 (5) 2.3 (1)
C(4) 0.0642 (5) 0.1307 (2) 0.4783 (5) 2.00 (9)
C(5) -0.1072 (5) 0.2020 (2) 0.3157 (6) 2.2 (1)
C(6) 0.0113 (6) 0.2372 (2) 0.2673 (5) 2.3 (1)
C(7) 0.2377 (6) 0.3036 (2) 0.3440 (6) 3.0 (1)
C(8) 0.3993 (6) 0.2959 (2) 0.4560 (6) 3.0 (1) TABLE 9 CONT'D
C(9) 0.5408 (6) 0.2477 (3) 0.4262 (6) 3.0 (1)
C(10) 0.2313 (6) 0.0015 (2) 0.3432 (6) 2.6 (1)
C(11) 0.0782 (6) -0.0238 (2) 0.2476 (6) 2.3 (1)
C(12) -0.1991 (6) 0.1048 (2) 0.3239 (7) 2.6 (1)
C(13) -0.3108 (6) 0.0941 (3) 0.1656 (7) 3.3 (1)
Anisotropic atoms are given in the form of:
Beq - (4/3) [a2β1,1 + b2β2,2 + c2β3,3 + ab(cos γ)β1,2 + ac(cos β)β1,3 + bc (cos α)β2,3]
TABLE 10
Crystal Data and Data Collections for GdL(15)-8H2O and GdL (16)-4H2O.
GdL (15)·8H2O GdL (16)·4H2O chemical formula GdC16H40N5O16 GdC17H34N5O12
formula weight 715.8 657.74
crystal 0.46 × 0.30 × 0.22 0.50 × 0.37 × 0.34 dimensions/mm
T/°C 21 23
F(000) 2904 1324
space group orthorhombic monoclinic
Pbca (No. 61) P21/c (No. 14)
cell parameters
a/Å 18.205 (1) 8.246 (2)
b/Å 18.930 (1) 14.995 (3)
c/Å 15.609 (1) 19.367 (4)
β/deg 90.00 90.258 (2)
V/Å3 5379 (1) 2395 (1)
Z 8 4
pcalcd/g cm-3 1.77 1.82
μ/cm-1 25.5 28.5
diffractometer used Enraf-Nonius CAD 4 Syntex P21
λ/Å (monochromated 0.71073 0.71073
Mo Kα)
scan method ω- 2θ θ-2θ TABLE 10 CONT'D
GdL (15) ·8H2O GdL (16) ·4H2O maximum 2θ 50° 50°
no. reflec collected 5269 4518 no. unique reflec 4741 4209 no. reflec with 3974 3661
I > 3.0σI
transmission 0.77 - 1.00 0.77 - 1.00 coefficient
R(Fo)a 0.026 0.021
R(Fo2)b 0.042 0.035 highest peak/e- Å-3 0.79 (8) 0.49 (7) min. neg. peak/e- Å- -0.14 (8) -0.42 (7) computer and program VAX/MolEN VAX/MolEN used aR(Fo) = ∑|Fo-Fc|/ΣFo. bR(Fo 2) = [(∑w(Fo-Fc)2/ΣwFo2)]1/2.
TABLE 11
Positional Parameters and Their Estimated Standard Deviations of GdL (15)·8H2O.
Atom x y z Beq2)
Gd 0.42584(1) 0.45223(1) 0.30709(1) 2.163(4)
O(1) 0.5543(1) 0.4714(1) 0.3476(2) 2.63(5)
O(2) 0.6391(1) 0.5538(1) 0.5589(2) 2.62(5)
O(3) 0.4089(2) 0.4461(1) 0.1561(2) 3.27(6)
O(4) 0.4035(2) 0.4949(2) 0.0272(2) 3.54(6)
O(5) 0.3209(1) 0.5243(2) 0.2820(2) 3.14(5)
O(6) 0.2309(1) 0.5899(2) 0.3335(2) 4.16(6)
O(7) 0.5011(1) 0.6419(1) 0.7477(2) 3.24(5)
O(8) 0.4135(1) 0.7199(2) 0.7200(2) 3.71(6)
N(1) 0.4980(2) 0.5467(2) 0.2190(2) 2.59(6)
N(2) 0.4240(1) 0.5850(2) 0.3804(2) 2.24(5)
N(3) 0.5337(1) 0.6574(1) 0.5705(2) 2.28(5)
N(4) 0.6849(2) 0.5990(2) 0.4372(2) 2.96(6)
N(5) 0.6695(2) 0.4940(2) 0.3003(2) 2.92(6)
C(1) 0.5983(2) 0.4898(2) 0.2899(2) 2.45(6)
C(2) 0.5680(2) 0.5102(2) 0.2032(2) 2.77(7)
C(3) 0.5121(2) 0.6146(2) 0.2646(2) 2.84(7)
C(4) 0.4469(2) 0.6372(2) 0.3156(2) 2.73(7)
C(5) 0.4719(2) 0.5844(2) 0.4577(2) 2.39(6)
C(6) 0.4679(2) 0.6498(2) 0.5147(2) 2.46(6)
C(7) 0.6004(2) 0.6697(2) 0.5188(2) 2.53(7)
C(8) 0.6427(2) 0.6025(2) 0.5056(2) 2.32(6)
C(9) 0.7383(2) 0.5432(2) 0.4230(3) 3.29(8)
C(10) 0.7061(2) 0.4781(2) 0.3806(2) 3.02(7)
C(11) 0.4603(2) 0.5599(2) 0.1368(2) 2.98(7)
C(12) 0.4220(2) 0.4948(2) 0.1035(2) 2.74(7)
C(13) 0.3468(2) 0.5989(2) 0.4013(2) 2.76(7)
C(14) 0.2957(2) 0.5687(2) 0.3335(2) 2.72(7) TABLE 11 CONT'D
Atom x y z Beq2)
C(15) 0.5186(2) 0.7168(2) 0.6293(2) 2.72(7)
C(16) 0.4727(2) 0.6914(2) 0.7043(2) 2.88(7)
O(w1) 0.3343(1) 0.3623(2) 0.2829(2) 3.66(6)
O(w2) 0.1181(2) 0.3667(2) 0.4733(2) 4.69(7)
O(w3) 0.4857(2) 0.3137(2) 0.0768(2) 4.78(7)
O(w4) 0.3547(2) 0.1352(2) 0.4782(2) 5.94(8)
O(w5) 0.1803(2) 0.2127(2) 0.1090(3) 7.9(1)
O(w6) 0.2944(2) 0.3047(2) 0.1229(3) 8.1(1)
O(w7) 0.1991(2) 0.3315(3) 0.3323(3) 10.0(1)
O(w8) 0.3362(3) 0.1872(3) 0.2119(3) 8.9(1)
Beq - (4/3) [a2B(1,1) + b2B(2,2) + c2B(3,3) + ab(cos γ)B(1,2) + ac(cos β)B(1,3) + bc(cos α)B(2,3)]
TABLE 12
Positional Parameters and Their Estimated Standard Deviations of YL(15)·8H2O.
Atom x y z Beq2)
Y 0.42741(4) 0.45211(5) 0.30519(5) 2.39(1)
O(1) 0.5519(3) 0.4713(3) 0.3479(3) 2.6(1)
O(2) 0.6356(3) 0.5540(3) 0.5624(3) 2.6(1)
O(3) 0.4106(3) 0.4444(3) 0.1568(4) 3.2(1)
O(4) 0.4008(4) 0.4932(4) 0.0270(4) 3.6(1)
O(5) 0.3245(3) 0.5200(3) 0.2800(4) 3.3(1)
O(6) 0.2315(3) 0.5857(4) 0.3289(4) 4.2(2)
O(7) 0.5000(3) 0.6395(3) 0.7481(4) 3.2(1) O(8) 0.4116(3) 0.7173(3) 0.7224(4) 3.8(2)
N(1) 0.4975(4) 0.5459(4) 0.2179(4) 2.5(1)
N(2) 0.4237(4) 0.5836(4) 0.3786(4) 2.4(1)
N(3) 0.5314(4) 0.6564(4) 0.5715(4) 2.3(2)
N(4) 0.6828(4) 0.5980(4) 0.4396(4) 2.9(2)
N(5) 0.6684(4) 0.4932(4) 0.3009(4) 2.9(2)
C(1) 0.5960(5) 0.4896(5) 0.2910(5) 2.7(2)
C(2) 0.5679(5) 0.5105(5) 0.2032(5) 3.0(2)
C(3) 0.5110(5) 0.6128(5) 0.2635(5) 3.1(2)
C(4) 0.4451(4) 0.6363(4) 0.3137(5) 2.7(2)
C(5) 0.4715(4) 0.5831(4) 0.4560(5) 2.4(2)
C(6) 0.4668(5) 0.6486(5) 0.5141(5) 2.8(2)
C(7) 0.5973(5) 0.6692(5) 0.5210(6) 2.9(2)
C(8) 0.6400(4) 0.6010(5) 0.5080(5) 2.2(2)
C(9) 0.7358(4) 0.5432(5) 0.4263(6) 3.3(2)
C(10) 0.7035(5) 0.4761(5) 0.3829(6) 3.2(2)
C(11) 0.4601(5) 0.5589(5) 0.1363(5) 3.4(2)
C(12) 0.4211(5) 0.4934(5) 0.1041(5) 2.9(2)
C(13) 0.3462(4) 0.5970(5) 0.3992(5) 2.8(2)
C(14) 0.2986(5) 0.5660(5) 0.3314(5) 2.9(2) TABLE 12 CONT'D
Atom x y z Beq2)
C(15) 0.5162(5) 0.7162(5) 0.6297(5) 2.9(2)
C(16) 0.4717(5) 0.6889(5) 0.7051(5) 3.0(2)
O(w1) 0.3383(3) 0.3642(3) 0.2827(4) 3.5(1)
O(w2) 0.1211(3) 0.3681(4) 0.4741(4) 4.6(2)
O(w3) 0.4871(4) 0.3155(4) 0.0772(5) 5.3(2)
O(w4) 0.3588(5) 0.1361(5) 0.4749(5) 7.9(2)
O(w5) 0.1785(4) 0.2123(5) 0.1126(6) 7.9(3)
O(w6) 0.2946(4) 0.3090(5) 0.1217(5) 7.5(2)
O(w7) 0.2002(4) 0.3303(6) 0.3342(5) 8.3(3)
O(w8) 0.3398(6) 0.1888(6) 0.2084(7) 11.9(3)
Beq - (4/3) [a2B(1,1) + b2B(2,2) + c2B(3,3) + ab(cos γ)B(1,2) + ac(cos β)B(1,3) + bc(cos α)B(2,3)]
TABLE 13
M-X and C-D Bond Distances (in A) in ML (15) -8H2O
(M = Gd or Y)
Gd Y
M-O(1)amide 2.449 (2) 2.403 (5)
M-O(2)amide 2.406 (2) 2.370 (5)
M-O(3)carboxylato 2.380 (3) 2.342 (5)
M-O(5)carboxylato 2.381 (3) 2.320 (6)
M-O(7)carboxylato 2.381 (3) 2.348 (6)
M-N(1)amine 2.611 (3) 2.589 (7)
M-N(2)amine 2.761 (3) 2.759 (7)
M-N (3)amine 2.915 (3) 2.926 (7)
M-O(w1)water 2.412 (3) 2.367 (6)
C(1)-O(1) 1.255 (4) 1.25 (1)
C(8)-O(2) 1.243 (4) 1.24 (1)
C(12)-O(3) 1.257 (5) 1.26 (1)
C(12)-O(4) 1.238 (4) 1.26 (1)
C(14)-O(5) 1.249 (5) 1.28 (1)
C(14)-O(6) 1.246 (4) 1.29 (1)
C(16)-O(7) 1.267 (4) 1.27 (1)
C(16)-O(8) 1.230 (5) 1.26 (1) TABLE 14
Bond Angles (in Degrees) around Metal in ML (15) 8H2O
(M = Gd or Y)
Gd Y
0(1) -M-O(2) 104.59 (8) 103.1 (2)
0(1)-M-O(3) 112.72 (9) 114.1 (2)
0(1) -M-O(5) 136.35 (9) 137.1 (2)
0(1)-M-O(7) 70.75 (8) 71.0 (2)
0(1)-M-N(1) 63.51 (9) 64.6 (2)
0(1)-M-N(2) 76.67 (8) 76.7 (2)
0(1)-M-N(3) 72.24 (8) 71.4 (2)
0(1)-M-)(w1) 143.59 (9) 143.5 (2)
0(2)-M-O(3) 142.68 (9) 142.7 (2)
0(2)-M-O(5) 77.04 (9) 77.3 (2)
0(2)-M-O(7) 123.44 (8) 123.2 (2)
0(2)-M-N(1) 137.55 (8) 137.3 (2)
0(2)-M-N(2) 71.16 (8) 70.8 (2)
0(2)-M-N(3) 61.36 (8) 61.1 (2)
0(2)-M-O(w1) 76.28 (9) 76.0 (2)
0(3)-M-O(5) 76.18 (9) 76.1 (2)
0(3)-M-O(7) 71.36 (9) 71.2 (2)
0(3)-M-N(1) 64.96 (9) 65.7 (2) TABLE 14 CONT'D
O(3)-M-N(2) 116.94 (8) 117.7 (2) O(3)-M-N(3) 130.33 (8) 129.8 (2) O(3)-M-O(wl) 73.82 (9) 73.6 (2) O(5)-M-0(7) 144.88 (9) 144.6 (2) O(5)-M-N(1) 85.66 (9) 85.9 (2) O(5)-M-N(2) 62.40 (8) 62.8 (2) O(5)-M-N(3) 135.97 (8) 135.7 (2) O(5)-M-O(w1) 79.88 (9) 79.1 (2) O(7)-M-N(1) 92.42 (9) 92.7 (2) O(7)-M-N(2) 146.72 (8) 146.9 (2) O(7)-M-N(3) 64.00 (8) 63.9 (2) O(7)-M-O(w1) 78.58 (9) 79.1 (2) N(1)-M-N(2) 66.47 (9) 66.6 (2) N(1)-M-N(3) 134.87 (8) 135.0 (2) N(1)-M-O(w1) 138.5 (1) 138.9 (2) N(2)-M-N(3) 112.29 (8) 112.1 (2) N(2)-M-O(w1) 134.33 (8) 133.5 (2) N(3)-M-O(w1) 77.00 (8) 76.9 (2)
TABLE 15
Positional Parameters and Isotropic Thermal Parametersor GdL (16)·4H2O.
Atom x y z Beq2
Gd 0.18531(2) 0.14340(1) 0.17534(1) 1.783(3)
O(1) 0.3071(2) 0.2896(2) 0.1528(1) 2.59(4)
O(2) -0.0280(2) 0.2527(1) 0.1539(1) 2.44(4)
O(3) 0.2354(3) 0.1406(2) 0.0549(1) 3.13(5)
O(4) 0.3865(3) 0.1159(2) -0.0373(1) 4.28(6)
O(5) 0.2757(3) -0.0037(2) 0.1825(1) 2.87(4)
O(6) 0.3601(4) -0.1218(2) 0.2411(2) 4.59(6)
O(7) 0.0206(2) 0.0792(2) 0.2636(1) 2.55(4)
O(8) -0.1099(3) 0.0816(2) 0.3632(1) 3.33(5)
N(1) 0.5058(3) 0.1441(2) 0.1371(1) 2.32(5)
N(2) 0.3788(3) 0.1159(2) 0.2807(1) 2.30(5)
N(3) 0.1149(3) 0.2554(2) 0.2777(1) 2.05(5)
N(4) -0.0123(3) 0.4018(2) 0.1377(1) 2.72(5)
N(5) 0.4187(4) 0.3522(2) 0.0582(2) 2.92(6)
C(l) 0.4198(4) 0.2956(2) 0.1097(2) 2.37(6)
C(2) 0.5639(4) 0.2353(2) 0.1199(2) 2.80(6)
C(3) 0.6033(4) 0.1053(3) 0.1934(2) 2.90(7)
C(4) 0.5475(4) 0.1426(2) 0.2626(2) 2.77(7)
C(5) 0.3277(4) 0.1705(3) 0.3409(2) 2.80(6)
C(6) 0.2647(4) 0.2613(2) 0.3214(2) 2.71(6)
C(7) 0.0711(4) 0.3431(2) 0.2486(2) 2.42(6)
C(8) 0.0035(3) 0.3295(2) 0.1762(2) 2.31(6)
C(9) -0.0293(4) 0.3987(3) 0.0630(2) 3.38(7)
C(10) 0.1222(5) 0.3640(2) 0.0270(2) 3.33(8)
C(11) 0.2789(4) 0.4132(2) 0.0476(2) 3.38(7)
C(12) 0.5042(4) 0.0897(2) 0.0740(2) 2.99(7)
C(13) 0.3673(4) 0.1180(2) 0.0263(2) 2.95(7)
C(14) 0.3739(4) 0.0193(2) 0.2975(2) 3.09(7) TABLE 15 CONT'D
Atom x y z Beq2
C(15) 0.3355(4) -0.0404(2) 0.2355(2) 2.89(6)
C(16) -0.0233(4) 0.2196(2) 0.3175(2) 2.43(6)
C(17) -0.0380(4) 0.1193(2) 0.3157(2) 2.31(6)
O(w1) -0.0326(3) 0.0590(2) 0.1163(1) 3.62(5)
O(w2) 0.6739(4) 0.1671(2) 0.9075(2) 5.57(7)
O(w3) 0.6665(3) 0.1605(2) 0.4542(1) 4.18(6)
O(w4) 0.9772(6) 0.0995(3) 0.9544(3) 12.1(1)
B,eq (4/3) [a 2·B(1,1) + b2B(2,2) + c2B(3,3) + ab(cos γ)B(1,2) + ac(cos β)B(1,3) + bc(cos α)B(2,3)]
TABLE 16
Selected Bond Distances (A) and Angles (°) In GdL(16)·4H2O
2.748 (3)
Bond
Distances
2.451 (2) Gd-N(1)amine
Gd- O(1)amide
Gd- O(2)amide 2.439 (2) Gd-N(2)amine 2.618 (2) Gd- 2.371 (2) Gd-N(3)amine 2.664 (2)
O(3)carboxylato
Gd- 2.332 (2) Gd-N(w1)water 2.474 (2)
O(5)carboxylato
Gd- 2.391 (2)
O(7)carboxylato
C(1)-O(1) 1.256 (4) C(15)-O(5) 1.264 (4) C(8)-O(2) 1.257 (4) C(15)-O(6) 1.242 (4) C(13)-O(3) 1.270 (4) C(17)-O(7) 1.272 (4) C(13)-O(4) 1.242 (4) C(17)-O(8) 1.234 (4)
Bond Angles
O(1)-Gd- 70.39 (7) O(1)-Gd- 76.55 (7)
O(2) O(3)
O(1)-Gd- 136.48 (7) O(1)-Gd- 136.23 (7) O(5) O(7)
O(1)-Gd- 63.47 (7) O(1)-Gd- 91.77 (7)
N(1) N(2)
O(1)-Gd- 70.11 (7) O(1)-Gd- 132.29 (8)
N(3) O(w1) TABLE 16 CONT'D
O(2)-Gd- 88.44 (8) O(2)-Gd- 151.15 (7)
O(3) O(5)
O(2)-Gd- 88.92 (7) O(2)-Gd- 130.20 (7)
O(7) N(1)
O(2)-Gd- 132.50 (8) O(2)-Gd- 62.87 (7)
N(2) N(3)
O(2)-Gd- 75.14 (7) O(3)-Gd- 89.11 (8)
O(w1) O(5)
O(3)-Gd- 142.98 (8) O(3)-Gd- 64.09 (8)
O(7) N(l)
O(3)-Gd- 131.00 (8) O(3)-Gd- 141.52 (8)
N(2) N(3)
O(3)-Gd- 70.46 (8) O(5)-Gd- 76.06 (8)
O(wl) O(7)
O(5)-Gd- 73.26 (7) O(5)-Gd- 67.12 (8)
N(1) N(2)
O(5)-Gd- 128.50 (8) O(5)-Gd- 76.96 (8)
N(3) O(w1)
O(7)-Gd- 138.10 (7) O(7)-Gd- 74.04 (7)
N(1) N(2)
O(7)-Gd- 66.13 (7) O(7)-Gd- 73.18 (8)
N(3) O(w1)
N(1)-Gd- 68.11 (8) N(1)-Gd- 114.28 (7)
N(2) N(3)
N(1)-Gd- 125.08 (8) N(1)-Gd- 69.70 (8)
O(w1) N(3)
N(2)-Gd- 135.93 (8) N(3)-Gd- 120.42 (7)
O(w1) O(w1)

Claims

CLAIMS :
1. A macrocyclic ligand according to the following formula:
Figure imgf000057_0001
wherein A is selected from the group consisting of:
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
- (CH2) x-NR2-(CH2)y-NR3-(CH2)z-;
B is selected from the group consisting of:
- (CH2) v-
Figure imgf000057_0002
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as either m or n;
and R1, R2, R3 is H or any alkyl group.
2. The macrocyclic ligand of claim 1 wherein m=l, A=(CH)x, and B=(CH2)v or
Figure imgf000057_0003
3. The macrocyclic ligand of claim 1 wherein m=l, A=(CH2)x, B=(CH2)v, v=2 and x=2.
4. The macrocyclic ligand of claim 1 wherein m=1, A=(CH2)x, B=(CH2)v, x=3 and v=2.
5. The macrocyclic ligand of claim 1 wherein A=(CH2)x,
Figure imgf000058_0001
m=1, x=2, v=2, t=2, and w=1.
6. The macrocyclic ligand of claim 1 wherein A=(CH2)x
Figure imgf000058_0002
m=1, x=3, v=2, w=1, and t=2.
7. A macrocyclic ligand according to the following formula:
Figure imgf000058_0003
wherein A is selected from the group consisting of
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
- (CH2)x-NR2-(CH2)y-NR3-(CH2)C-; B is selected from the group consisting of
-(CH2)v-
Figure imgf000059_0001
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n;
and R1, R2, R3 is H or any alkyl group.
8. The macrocyclic ligand of claim 7 wherein A =(CH2)x and B =(CH2)v.
9. The macrocyclic ligand of claim 7 wherein m=1, A=(CH2)x, B=(CH2)v, x=2 and v=2.
10. A macrocyclic ligand according to the following formula:
Figure imgf000059_0002
wherein A is selected from the group consisting of:
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
- (CH2)x-NR2-(CH2)y-NR3-(CH2) -; B is selected from the group consisting of:
-(CH2)v-
Figure imgf000060_0001
C is selected from the group consisting of:
-(CH2)v-
Figure imgf000060_0002
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n; and
R1, R2, R3 is H or any alkyl group.
11. A macrocyclic ligand according to the following formula:
Figure imgf000060_0003
12 . A macrocyclic ligand according to the following formula :
Figure imgf000061_0001
13. A macrocyclic ligand according to the following formula:
Figure imgf000061_0002
14. A macrocyclic ligand according to the following formula:
Figure imgf000061_0003
15. A macrocyclic ligand according to the following formula:
Figure imgf000062_0001
16. A complex of a metal selected from the group consisting of any metal ion that is in the +1, +2, +3, or +4 oxidation state with a macrocyclic ligand having the formula:
Figure imgf000062_0002
wherein A is selected from the group consisting of:
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
- (CH2)x-NR2-(CH2)y-NR3-(CH2)z-;
wherein B is selected from the group consisting of:
-(CH2)v-
Figure imgf000063_0001
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n; and
R1, R2, R3 is H or any alkyl group.
17. The complex of claim 16 wherein m=1, A=(CH2)x, B=(CH2)v, x=2, and v=2.
18. The complex of claim 17 wherein the metal is any divalent metal ion.
19. The complex of claim 17 wherein the metal is copper (II).
20. The complex of claim 16 wherein m=1, A=(CH2)x, B=(CH2)v, x=3 and v=2.
21. The complex of claim 20 wherein the metal is any divalent metal ion.
22. The complex of claim 20 wherein the metal is manganese (II).
23. The complex of claim 20 wherein the metal is lead (II).
24. The complex of claim 16 wherein
A=(CH2)x
Figure imgf000064_0001
m=1, v=2, x=2, w=1, and t=2.
25. The complex of claim 24 wherein the metal is any trivalent metal ion.
26. The complex of claim 25 wherein the metal is gadolinium(III).
27. The complex of claim 25 wherein the metal is yttrium(III).
28. The complex of claim 16 wherein A=(CH2)x
Figure imgf000064_0002
m=1, x=3, v=2, w=1, and t=2.
29. The complex of claim 28 wherein the metal is any trivalent metal ion.
30. The complex of claim 28 wherein the metal is gadolinium(III).
31. A complex of a metal selected from the group consisting of any metal ion that is in the +1, +2, +3 or +4 oxidation state with a macrocyclic ligand having the formula:
Figure imgf000065_0001
wherein A is selected from the group consisting of:
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
- (CH2)x-NR2-(CH2)y-NR3-(CH2)z-;
B is selected from the group consisting of:
-(CH2)v-
Figure imgf000065_0002
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n; and
R1, R2, R3 is H or any alkyl group.
32. The complex of claim 31 wherein m=1, A=(CH2)x, B=(CH2)v, x=2 and v=2.
33. The complex of claim 32 wherein the metal is any divalent metal ion.
34. The complex of claim 32 wherein the metal is manganese (II).
35. The complex of claim 32 wherein the metal is cobalt (II).
36. A method for enhancing contrast in imaging techniques used on living subjects, which includes administering internally to the subject an effective amount of a contrast agent which comprises a complex of a metal selected from the group consisting of any metal ion that is in the +1, +2, +3 or +4 oxidation state and a macrocyclic ligand having the formula:
wherein A is selected from the group consisting of:
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
-(CH2)x-NR2-(CH2)y-NR3-(CH2)z-;
B is selected from the group consisting of:
-(CH2)v-
Figure imgf000066_0002
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n; and
R1, R2, R3 is H or any alkyl group.
37. The method of claim 36 wherein m=1,
A=(CH2)x, B=(CH2)v, v=2 and x=2.
38. The method of claim 37 wherein the metal is any divalent metal ion.
39. The method of claim 37 wherein the metal is copper (II).
40. The method of claim 36 wherein m=1, A=(CH2)x, B=(CH2)v, x=3, and v=2.
41. The method of claim 40 wherein the metal is any divalent metal ion.
42. The method of claim 40 wherein the metal is lead(II).
43. The method of claim 40 wherein the metal is manganese (II).
44. The method of claim 36 wherein A=(CH2)x
Figure imgf000067_0001
m=1, x=2, w=1, t=2 and v=2.
45. The method of claim 44 wherein the metal is any trivalent metal ion.
46. The method of claim 44 wherein the metal is gadolinium(III).
47. The method of claim 44 wherein the metal is yttrium(III).
48. The method of claim 36 wherein
A=(CH2)x
Figure imgf000068_0001
m=1, x=3, t=2, w=1 and v=2.
49. The method of claim 48 wherein the metal is any trivalent metal ion.
50. The method of claim 48 wherein the metal is gadolinium (III).
51. A method for enhancing contrast in imaging and diagnostic techniques used on living subjects, which includes administering internally to the subject an effective amount of a contrast agent which comprises a complex of a metal selected from the group consisting of any metal ion that is in the +1, +2, +3 or +4 oxidation state and a macrocyclic ligand having the formula:
Figure imgf000068_0002
wherein A is selected from the group consisting of:
-(CH2)x-
-(CH2)x-NR1-(CH2)y-
- (CH2)x-NR2-(CH2)y-NR3-(CH2)z-; B is selected from the group consisting of:
-(CH2)v-
Figure imgf000069_0001
and wherein m, n, t, u, v, w, x, y, z are independently selected from the integers 1, 2, 3, 4;
w is selected to be the same as m or n; and
R1, R1, R2 is H or any alkyl group.
52. The method of claim 51 wherein m=1, A=(CH2)x, B=(CH2)v, x=2, and v=2.
53. The method of claim 52 wherein the metal is any divalent metal ion.
54. The method of claim 52 wherein the metal is manganese (II).
55. The method of claim 52 wherein the metal is cobalt (II).
56. A method for synthesizing macrocyclic ligands with pendant carboxylic acid groups comprising the steps of:
providing a polyalkylpolyaminopolycarboxylic dianhydride;
providing an alkylpolyamine or polyalkylpolyamine; reacting the polyalkylpolyaminopolycarboxylic dianhydride and the polyalkylpolyamine under conditions sufficient to cause the synthesis of the macrocyclic ligands with pendant carboxylic acid groups.
57. The method of claim 56 wherein the
polyalkylpolyaminopolycarboxylic dianhydride is
ethylenediaminetetraacetic dianhydride and the
alkylpolyamine or polyalkylpolyamine is ethylenediamine.
58. The method of claim 56 wherein the
polyalkylpolyaminopolycarboxylic dianhydride is
ethylenediaminetetraacetic dianhydride and the
alkylpolyamine or polyalkylpolyamine is
1,3-diaminopropane.
59. The method of claim 56 wherein the
alkylpolyamine or polyalkylpolyaminopolycarboxylic dianhydride is diethylenetriaminepentaacetic dianhydride and the polyalkylpolyamine is ethylenediamine.
60. The method of claim 56 wherein the
polyalkylpolyaminopolycarboxylic dianhydride is
diethylenetriaminepentaacetic dianhydride and the
alkylpolyamine or polyalkylpolyamine is propylenediamine.
61. The complex of claim 16 wherein two of said metal ions complex with two of said ligands.
62. The complex of claim 16 wherein two of said metal ions complex with one of said ligands.
63. A complex of two metal ions selected from the group consisting of metal ions that are in the +1, +2, +3 or +4 oxidation state with two macrocyclic ligands having the following formula:
Figure imgf000071_0001
64. The complex of claim 63 wherein the metal ions are selected from the group consisting of
gadolinium(III) and yttrium (III).
65. The complex of claim 31 wherein two of said metal ions complex with two of said ligands.
66. The complex of claim 31 wherein two of said metal ions complex with one of said ligands.
67. A complex of two metal ions selected from the group consisting metal ions that are in the +1, +2, +3 or +4 oxidation state with a macrocyclic ligand having the following formula:
Figure imgf000071_0002
68. The complex of claim 67 wherein the metal ions are manganese (II),
PCT/US1993/005532 1992-06-10 1993-06-10 Metal complexes formed with macrocyclic ligands for use in imaging techniques WO1993025243A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89611892A 1992-06-10 1992-06-10
US07/896,118 1992-06-10
US92783692A 1992-08-10 1992-08-10
US07/927,836 1992-08-10

Publications (2)

Publication Number Publication Date
WO1993025243A2 true WO1993025243A2 (en) 1993-12-23
WO1993025243A3 WO1993025243A3 (en) 1994-05-26

Family

ID=27129131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/005532 WO1993025243A2 (en) 1992-06-10 1993-06-10 Metal complexes formed with macrocyclic ligands for use in imaging techniques

Country Status (1)

Country Link
WO (1) WO1993025243A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721361A (en) * 1995-06-07 1998-02-24 The Monsanto Company Process for preparing substituted polyazamacrocycles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0461413A1 (en) * 1990-05-17 1991-12-18 Fuji Photo Film Co., Ltd. Processing compositions for silver halide color photographic materials and method for processing the same materials
WO1992008707A1 (en) * 1990-11-07 1992-05-29 Cockbain, Julian, Roderick, Michaelson Chelating agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0461413A1 (en) * 1990-05-17 1991-12-18 Fuji Photo Film Co., Ltd. Processing compositions for silver halide color photographic materials and method for processing the same materials
WO1992008707A1 (en) * 1990-11-07 1992-05-29 Cockbain, Julian, Roderick, Michaelson Chelating agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOPUXUE ZAZHI, vol.7, no.2, 1990, CHINA pages 225 - 230 Z. ANJIANG ET AL. 'ASSIGNEMENT OF PROTON AND CARBON-13 NMR CHEMICAL SHIFTS OF CROWN ETHER DERIVATIVES OF EDTA AND 4'-(DANSYLAMINO)BENZO CROWN ETHERS' *
CHEMICAL ABSTRACTS, vol. 109, no. 12, 19 September 1988, Columbus, Ohio, US; abstract no. 99547n, F. YIJUN ET AL. 'DETERMINATION OF THE ACID DISSOCIATION CONSTANT AND COMPLEX STABILITY CONSTANT OF CROWN ETHER DERIVATIVES OF EDTA' & SICHUAN DAXUE XUEBAO, ZIRAN KEXUEBAN, vol.24, no.4, 1987 pages 515 - 517 *
INORGANIC CHEMISTRY, vol.31, no.12, 10 June 1992 pages 2480 - 2483 M.B. INOUE ET AL. 'NEW 12-MEMBERED AND 24-MEMBERED MACROCYCLES WITH PENDENT ACETATO GROUPS AND X-RAY CRYSTAL STRUCTURES OF THE COPPER(II) AND MANGANESE(II) COMPLEXES' *
INORGANIC CHEMISTRY, vol.31, no.20, 30 September 1992 pages 4065 - 4068 J.F. CARVALHO ET AL. 'SYNTHESIS AND METAL COMPLEX SELECTIVITY OF MACROCYCLIC DTPA AND EDTA BIS(AMIDE) LIGANDS' *
YOUJI HUAXUE, vol.4, 1984, CHINA pages 290 - 292 Q. SHENGYING 'SYNTHESIS OF A SERIES OF NEW N,N'-DICARBOXYMETHYL MACROCYCLIC ETHYLENEDIAMINETETRAACETIC ACID' *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721361A (en) * 1995-06-07 1998-02-24 The Monsanto Company Process for preparing substituted polyazamacrocycles

Also Published As

Publication number Publication date
WO1993025243A3 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
Gorun et al. Synthesis, structure, and characterization of the tetranuclear iron (III) oxo complex [Fe4O2 (BICOH) 2 (BICO) 2 (O2CPh) 4] Cl2
Kovala-Demertzi et al. Metal complexes of the anti-inflammatory drug sodium [2-[(2, 6-dichlorophenyl) amino] phenyl] acetate (diclofenac sodium). Molecular and crystal structure of cadmium diclofenac
Livage et al. Hybrid open frameworks (MIL-n). Part 5 Synthesis and crystal structure of MIL-9: a new three-dimensional ferrimagnetic cobalt (II) carboxylate with a two-dimensional array of edge-sharing Co octahedra with 12-membered rings
Long et al. Restraining symmetry in the formation of small polyoxomolybdates: Building blocks of unprecedented topology resulting from “shrink-wrapping”[H 2 Mo 16 O 52] 10−-type clusters
Charlot et al. Crystal structure and magnetic properties of tetrakis (cyclohexylamine) di-. mu.-hydroxo-dicopper (II) perchlorate. The first example of a roof-shaped hydroxo-bridged copper (II) dimer
Zheng et al. Syntheses and characterization of Co2 (4, 4′-bipy) 2 (V4O12), Co (pz)(VO3) 2 and Co2 (2-pzc)(H2O)(VO3) 3 (4, 4′-bipy= 4, 4′-bipyridine, pz= pyrazine, 2-pzc= 2-pyrazinecarboxylate)
Brand et al. An oxo-bridged binuclear vanadium (III) 2, 2'-bipyridine complex and its vanadium (IV) and vanadium (V) oxidation products
Cariati et al. Interaction of metal ions with humic-like models. Part. I. Synthesis, spectroscopic and structural properties of diaquabis (2, 6-dihydroxybenzoato) copper (II) and hexaaquaM (II) bis (2, 6-dihydroxybenzoate) dihydrate (M= Mn, Fe, Co, Ni, Cu and Zn)
Bag et al. Fixation of carbon dioxide by macrocyclic lanthanide (III) complexes under neutral conditions producing self-assembled trimeric carbonato-bridged compounds with μ 3-η 2: η 2: η 2 bonding
Ding et al. Mono-, Tetra-and octanuclear transition metal complexes of in situ generated schiff base ligands containing up to 12 coordinating atoms: syntheses, structures and magnetism
Yevitz et al. Structures of the oxo-and hydroxo-bridged, binuclear chromium (III)-ammine complexes. Rhodo and erythro series
Kahwa et al. The first crystal and molecular structure of lanthanide homodinuclear macrocyclic complexes showing metal–metal pair interactions
Caulton et al. Synthesis and molecular structure of a mononuclear barium aryloxide-ethanolamine complex, Ba (2, 6-tert-Bu2C6H3O) 2 (HOCH2CH2NMe2) 4. cntdot. 2C7H8, exhibiting extensive hydrogen bonding
Suresh et al. Metal–α, ω-dicarboxylate complexes. I. Aqua (2, 2'-bipyridyl-N, N')(malonato-O, O') copper (II) monohydrate
Saadeh et al. Structural and magnetic characterization of alternating AB chains of composition [(Cat) 2 {MnIII (malonate) 2 (CH3OH) 2][MnIII (malonate) 2]}] n and (Cat) 2 [[MnIII (malonate) 2 (CH3OH)][MnIII (malonate) 2]] n
Ishida et al. Preparation and properties of molybdenum and tungsten dinitrogen complexes. 38. Hydrido-carbonato, hydrido-carbamato, and carbon dioxide complexes of tungsten derived from the carbonyl-dinitrogen complex trans-[W (CO)(N2)(Ph2PCH2CH2PPh2) 2]
Nour et al. Synthesis and Spectroscopic Studies of NN-O-Phenylenebis (Salicylideneiminato) Dioxouranium (VI) Solvates (L) CL= DMF and PY
Inoue et al. Syntheses of new 15-membered and 16-membered macrocyclic ligands with three pendant acetato groups and the structures of the gadolinium (III) complexes
Depree et al. Monomeric, trimeric and polymeric assemblies of dicopper (II) complexes of a triazolate-containing Schiff-base macrocycle
Drewes et al. Synthesis and structure of a novel type of polyoxomolybdate lanthanide complex:[(Ln (H2O) 6) 2 (TeMo6O24)](Ln= Ho, Yb)
Smith et al. Metal–phenoxyalkanoic acid interactions. Part 13. Copper (II)–(2-chlorophenoxy) ethanoic acid complexes. Crystal and molecular structures of catena-tetra-µ-[(2-chlorophenoxy) ethanoato-O, O′]-dicopper (II), catena-(2-aminopyrimidine-N, N′)-tetra-µ-[(2-chlorophenoxy) ethanoato-O, O′]-dicopper (II), and 1, 2, 2, 2, 2-penta-aqua-tetra-µ-[(2-chlorophenoxy)-ethanoato-O, O′]-copper (II) calcium (II)
WO1993025243A2 (en) Metal complexes formed with macrocyclic ligands for use in imaging techniques
Messimeri et al. Synthesis and physical studies of lanthanide (III) complexes of N, N-bis (2-hydroxyethyl) glycinate (bicinate, bicH2−): molecular and crystal structure of [Gd (O2CMe)(bicH2)(phen)(H2O)](ClO4). phen. 3H2O (phen= 1, 10-phenanthroline)
Buckingham et al. Reactions of coordinated nucleophiles. Formation and structure of a novel tridentate complex
Tarulli et al. Structural and Spectroscopic Characterization of Bis (thiosaccharinato)‐trispyridine‐cadmium (II)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

NENP Non-entry into the national phase in:

Ref country code: CA

122 Ep: pct application non-entry in european phase